WO2002096909A1 - Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors - Google Patents

Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors Download PDF

Info

Publication number
WO2002096909A1
WO2002096909A1 PCT/IB2002/001905 IB0201905W WO02096909A1 WO 2002096909 A1 WO2002096909 A1 WO 2002096909A1 IB 0201905 W IB0201905 W IB 0201905W WO 02096909 A1 WO02096909 A1 WO 02096909A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
amino
alkoxy
compound
methyl
Prior art date
Application number
PCT/IB2002/001905
Other languages
French (fr)
Inventor
Glenn Ernest Wilcox
Christian Koecher
Ton Vries
Mark Edward Flanagan
Michael John Munchhof
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002096909(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA002448281A priority Critical patent/CA2448281C/en
Priority to AU2002304401A priority patent/AU2002304401C1/en
Priority to EEP200300594A priority patent/EE05332B1/en
Priority to UA20031110841A priority patent/UA80093C2/en
Priority to PL409305A priority patent/PL228155B1/en
Priority to KR10-2003-7015681A priority patent/KR20040003037A/en
Priority to SK1465-2003A priority patent/SK288199B6/en
Priority to MXPA03011062A priority patent/MXPA03011062A/en
Priority to NZ530380A priority patent/NZ530380A/en
Priority to KR1020087018519A priority patent/KR100926875B1/en
Priority to EA200301193A priority patent/EA007251B1/en
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to JP2003500088A priority patent/JP4381137B2/en
Priority to SK50033-2011A priority patent/SK288192B6/en
Priority to IL15858802A priority patent/IL158588A0/en
Priority to HU0400152A priority patent/HU230876B1/en
Priority to EP02733058A priority patent/EP1392694A1/en
Priority to BR0209246-8A priority patent/BR0209246A/en
Publication of WO2002096909A1 publication Critical patent/WO2002096909A1/en
Priority to IS6993A priority patent/IS3023B/en
Priority to HR20030943A priority patent/HRP20030943B1/en
Priority to NO20035201A priority patent/NO328578B1/en
Priority to BG108389A priority patent/BG66489B1/en
Priority to AU2008203170A priority patent/AU2008203170B2/en
Priority to NO20093135A priority patent/NO20093135L/en
Priority to NO2017047C priority patent/NO2017047I1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • R 6 , R 7 , R s , R s , R 10 and R 11 are each independently selected from the group consisting of hydrogen or (CrC 6 )alkyI optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C C 8 )acyloxy, (C C 6 )acylamino, (C C 6 )alkylamino, ((C
  • (C 2 -Cj ⁇ )Heterocycloalkyl when used herein refers to pyrrolidinyi, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyra ⁇ yl, azirid ⁇ nyl, oxira ⁇ yl, methylenedioxyl, chromenyl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thia2olidin-3-yl, 1 ,2-pyrazolidin-2-yt, 1,3-pyrazolidi ⁇ -1-yl, piperidinyl, thiomorpholi ⁇ yl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yI, tetrahydrothiadiazinyl, morpholinyl, 1 ,2-tetrahydrodiazin-2-yl, 1,3-te
  • the present invention also relates to a method for treating or preventing a disorder or condition selected from organ transplant rejection, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis.
  • a disorder or condition selected from organ transplant rejection, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis.
  • Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia, and other autoimmune diseases in a mammal, including a human comprising administering to said mammal an amount of an above described specifically preferred compound or a pharmaceutically acceptable salt thereof, effective in treating such a condition.
  • reaction 2 of Preparation A the 4-chloro-5-halopyrrolo(2,3-d]pyrimidine compound of formula XX, wherein R is hydrogen, is converted to the corresponding compound of formula XIX, wherein R 2 is (C ⁇ -C 6 )alkyl or benzyl, by treating XX with N- butyllithium, at a temperature of about ⁇ 78°C, and reacting the dianion intermediate so formed with an alkylhalide or be ⁇ zylhalide at a temperature between about -78°C to room temperature, preferably room temperature.
  • reaction 3 of Scheme 1 removal of the protecting group from the compound of formula XV, wherein R is benzenesulfonyl, to give the corresponding compound of formula I, is carried out by treating XV with an alkali base, such as sodium hydroxide or potassium hydroxide, in an alcohol solvent, such as methanol or ethanol, or mixed solvents, such as alc ⁇ hol/tetrahydrofuran or alcohol/water.
  • an alkali base such as sodium hydroxide or potassium hydroxide
  • alcohol solvent such as methanol or ethanol
  • mixed solvents such as alc ⁇ hol/tetrahydrofuran or alcohol/water.
  • the reaction is carried out at room temperature for a time period between about 15 minutes to about 1 hour, preferably 30 minutes.
  • Removal of the protecting group from the compound of formula XV, wherein R is benzyl is conducted by treating XV with sodium in ammonia at a temperature of about -78°C for a time period between about 15 minutes to about 1 hour.
  • mycophenolate e.g. Cellcept®, azathioprine (e.g. Imuran®), daclizumab (e.g. Zenapax®), OKT3 (e.g. Orthocolone

Abstract

A method for resolving enantiomers of a compound containing the structure of the formula (I): wherein R4 or R5 may contain one or more asymmetric centers, by mixing a racemic mixture of enantiomers of a compound, containing the structure of said formula; in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with said resolving agent being capable of binding with at least one but not all of said enantiomers to form a precipitate, containing said at least one of said enantiomers in stereospecific form and collecting either the precipitate and purifying it or collecting the solution with contained other of said enantiomers and recrystalizing the enantiomer contained in said solution.

Description

OPTICAL RESOLUTION OF ( 1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO λ 2 , 3 ! PYRIMIDINE DERIVATIVES AS
PROTEIN KINASES INHIBITORS
CHIRAL SALT RESOLUTION Field of the Invention The present invention relates to methods for effecting chiral salt resolution from racemic mixtures of enantiomers and particularly precursor enantiomers used 5 in making pyrrolo[2,3-d]pyrimidine compounds, which are inhibitors of protein kinases. The present invention also relates to pyrrolol[2,3-d]ρyτimidine compounds and methods of using such compounds as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.
Background of the Invention
10 Pyrrolo[2,3-d]pyrimidine compounds are inhibitors of protein kinases, such as the enzyme Janus Kinase 3 (JAK3) and are therefore useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders,
15 ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other indications where immunosuppression would be desirable. The pyrrolo[2,3- d]pyrimidine compounds, pharmaceutical compositions thereof and methods of use are described in co-pending application serial no. 09/732669, filed December 8, 2000, and assigned to the assignee of the present invention. The disclosure of said
20 application is included in its entirety herein by reference thereto. Racemic mixtures of the pyrrolo[2,3-d]pyrimidine compounds are initially obtained whereas the individual enantiomers in substantially isolated pure form are preferred and at times required for drug use. It is possible to pre-ordain the stereochemistry of the compounds by use of stereospecific precursor compounds in the sythesis thereof.
25 The methods of the present invention accordingly specifically relate to a method for the substantial chiral salt resolution of racemic mixtures of precursor compounds, used in the production of the separate enantiomeric forms of the pyrrolo[2,3- d]pyrimidine compounds.
Summary of the Invention
30 The present invention relates to methods for resolving the enantiomers of the precursors used in preparing a compound of the following formula and particularly the R1 group thereof:
Figure imgf000003_0001
or the pharmaceutically acceptable salt thereof; wherein R1 is a group of the formula
Figure imgf000003_0002
wherein y is 0, 1 or 2;
R4 is selected from the group consisting of hydrogen, (C C6)alkyl, (C Ce)alkylsulfonyl, (d-d alkenyl, (C2-C6)alkynyl wherein the alkyl, alkenyl and alkynyl groups are optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C,- C )alkoxy, (C C6)acyloxy, (d-C6)alkylamino, ((CrC6)alkyl)2amino, cyano, nitro, (C2-C6)alkenyl, (C2-Ce)alkyπyl or (d-C6)acylamino; or R4 is (C3-C10)cycloalkyl wherein the cycloalkyl group is optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-Cβ)acyloxy, (d-Ca)acylamiπo, (Cι-C6)alky!amino, ((C,- CB)alkyl)2amino, cyano, cyano(CrC6)alkyl, trifluoromethyl (C1-C8)alkyl, nitro, nitro(Cι-Ce)alkyl or (C C6)acylamino; Rs is (d-CgJheterocycloalkyl wherein the heterocycloalkyl groups must be substituted by one to five carboxy, cyano, amino, deuterium, hydroxy. (CrCB)alkyl, (d-CB)alkoxy, halo, (CrCB)acyi, (d-CeJalkylamino, amiπo(Cι-CB)alkyl, (C C6)alkoxy-CO-NH, (CrC6)alkylamino-CO-, (C2-C6)alkenyl, (C2-C6) alkynyl, (C C6)alkylamino, amino(CrC6)alkyl, hydroxy(C Ce)alkyl, (d-C6)alkoxy(C Cβ)alkyl, (d-C6)acyloχy(C Ce)alkyl, nitro, cyano(C Cβ)alkyl, halo(C C$)alkyl, nitro(d- C6)alkyl, trifluoromethyl, trifluoromethyl(CrC6)alkyl, (d-CeJacylamino, (C C6)acylamiπo(C1-Ce)alkyl, (C1-C6)alkoxy(C1-Ce)acylamino, amino(d-Cβ)acyl,
Figure imgf000003_0003
(d-CeJalkylaminofCi-CβJacyl, ((d-
C6)alkyl)2amino(C CB)acyl, R15R1βN-CO-0-, R1sR16N-CO-(CrC6)alkyl, (CrC6)alkyl- S(0)m, R15RlβNS(0)m, R15R1?NS(0)m (d-C6)alkyl. R15S(0)m R16N, R15S(0)mR1eN(C Cβ)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (CrCG)alkyl; or a group of the formula II
Figure imgf000004_0001
wherein a is 0, 1 , 2, 3 or 4; b, c, e, f and g are each independently 0 or 1 ; d is O, 1, 2, or 3; X is S(0)n wherein n is 0, 1 or 2; oxygen, carbonyl or -C(=N-cyano)-;
Y is S(0)n wherein n is 0, 1 or 2; or carbonyl; and
Z is carbonyl, C(0)0-, C(0)NR- or S(0)n wherein n is 0„1 or 2;
R6, R7, Rs, Rs, R10 and R11 are each independently selected from the group consisting of hydrogen or (CrC6)alkyI optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C C8)acyloxy, (C C6)acylamino, (C C6)alkylamino, ((C
CβJalky zaminα, cyano, cyaπo(d-C6)alkyl, trrfluoromethyl(Cι-C6)alkylt nitro, nitro(d-Ce)aIkyl or (d-C3)acylamino;
R1Z is carboxy, cyano, amino, oxo, deuterium, hydroxy, trifluoromethyl, (CrC6)alkyl. trifluorσmethyl(d-C6)alkyl, (d-C6)alkoxy, halo, <d-Cβ)acyl, (d-C„)alkylamino, ((C Ce)alkyl)2 amino, amino(C C6)alkyl, (d-C6)alkoxy-CO-NH, (CrC6)alkylamino-CO-,
(Cz-Ce)alkenyl, (C Cs) alkynyl, (CrC6)alkylamino, hydroxy(CrC6)alkyI, (d-
C6)alkoxy(CrC6)alkyl, (d-Cβ)acyloxy(C Ca)alkyl, nitro, cyaπo(C CB)alkyl, halo(C
C6)alkyl, nitro(C1-Ce)alkyl, trifluoromethyl, trifluoromethyl(d-C6)alkyl, (Cr
C8)acylamino, (CrC6)acylamino(C C6)alkyl, (CrCe)alkoxy(Cι-C6)acylamino, amino(C,-C6)acyl, amino(C C6)acyl(C C6)alkyl, (d-Ce)alkylamino(d-C6)acyl, ((C
C6)alkyl)2amino{CrC6)acyl, R15R1βN-CO-0-, RlSR16N-CO-(d-C6)alkyl, R1SC(0)NH,
R15OC(0)NH, R 5NHC(0)NH, (C,-Ce)alkyl-S(0)m. (CrC6)alkyl-S(0)m-(CrC6)alkyl,
R15R1βNS(0)m, R,5R1βNS(Q)m (CrC.)alkyl, R15S(0)m R16N, Rl5S(0)mR1BN(d-C6)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (Cι-C6)alkyl;
Rz and R3 are each independently selected from the group consisting of hydrogen, deuterium, amino, halo, hydoxy, nitro, carboxy, (Cz-C6)alkenyl, (CrC0)alkynyl, trifluoromethyl, trifluoromethαxy, (d-Ce)alkyl, (d-C6)alkoxy, (C3-C10)cycloalkyl wherein the alkyl, alkoxy or cycloalkyl groups are optionally substittued by one to three groups selected from halo, hydroxy, carboxy, amino (d-Cβ)aIkylthio, (Cr Ce)alkylamino, ((CrC6)alkyl)z.amino, (Cg-Cgjheteroaryl, (Cz-C8)heterocycloalkyl, (C3- C9)cycloalkyl or (C6-C10)aryl; or R2 and R3 are each independently (C3-C10)cycloalkyl, (C3-C10)cycloalkoxy, (CrC6)aIkylamino, ((C C6)alkyl)2amiπo, (C6-C10)arylamiπo, (C CB)alkylthio, (C6-Cι0)arylthio, (C C6)alkylsulfιnyl, (C6-do)arylsulfιnyl, (Cr Ce)alkylsulfonyl, (CQ-C10)arylsulfonyl, (C CB)acyl, (C C5)alkoxy-CO-NH-, (C CB)alkyamino-CO-, (C5-C9)heteroaryl, (CrC9)heterocycloalkyl or (C6-C10)aryl wherein the heteroaryl, heterocycloalkyl and aryl groups are optionally substituted by one to three halo, (CrC6)alkyl, (CrCe)alkyl-CO-NH-, (d-CB)alkoxy-CO-NH-, (CrC6)alkyl- CO-NH-(C Ce)alkyl, (CrC6)alkoxy-CO-NH-(CrCe)alkyl, (CrC6)aIkoxy-CO-NH-(d- Cs)alkoxy, carboxy, carboxy(Cι-C6)alkyl, carboxy(CrCe)alkoxy, benzylαxycarbonyl(CrCβ)alkoxy, (d-CeJalkoxycarbony d-Cetelkoxy, (C6-C10)aryl, amino, amino(d-C3)alkyl, (CTC^alkoxycarbonylamirio, (C6-C1β)aryl(Cr Ce)alkoxycarbonylamino, (C C6)alkylamino, ((d-CeJalky jamiπα, (C Cs)alkylamino(C Ce)alkyl, ((CrCB)alkyl)2amino(C Ce)alkyl, hydroxy, (CrCs)alkoxy, carboxy, carboxy(d-Ce)alkyl, (d-Ce)alkoxycarbonyl, (d-C6)alkoxycarbonyl(C CB)alkyl, (C Ce)alkoxy-CO-NH-, (C C6)alkyl-CO-NH-, cyano, (Cs-Cg)heterocycloalkyl, amino-CO-NH-, (d-C3)alkylamino-CO-NH-, ((CrCβ)alkyl)2amino-CO-NH-, (C6- do)arylamino-CO-NH-, (C3-C9)heteroarylamino-CO-NH-, (CrCs)alkylamino-CO-NH- (d-C6)alkyl, ((C^CeJalkyDjamino-CO-NH-CCrCeJalkyl, (C6-C10)arylamino-CO-NH-(C C6)alkyl, (CrCg)heteroarylamino-CO-NH-(CrC6)alkyI, (C -Cβ)alkylsulfonyl, (Cr Ce)alkylsulfonylamino, (d-CeJalkylsuIfonylaminotd-CeJalkyl, (CB-C10)arylsulfonyl, (C6- Cιo)arylsulfonylamino, (Cβ-C10)arylsulfoπylamino(Cι-C6)alkyl, (Cr C6)alkylsulfonylamino, {Ci-CeJalkylsulfonylaminoCCi-CeJalkyl, (Cs-Cgjheteroaryl or (C2- Cg)heterocycloalkyl.
The present invention also relates to the production of stereospecific pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, add phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methaπesulfoπate, ethanesulfonate, benzenesulfonate, p-toluenesulfoπate and pamoate [Le., 1,1'-methylene-bis-(2-hydroxy-3- naphthoate)]salts.
The invention also relates to stereospecific base addition salts of formula I.
The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water- soluble amine addition salts such as N-methylglucamine-(meglumiπe), and the lower alkanolamrnoπium and other base salts of pharmaceutically acceptable organic
' amines.
The term "alkyl", as used herein, unless otherwise indicated, includes
•r saturated monovalent hydrocarbon radicals having straight or branched moieties or combinations thereof.
The term "alkoxy", as used herein, includes O-alkyl groups wherein "alkyl" is defined above.
The term "halo", as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo. The compounds of this invention may contain double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof. Unless otherwise indicated, the alkyl and alkenyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e.g.. alkoxy), may be linear or branched, and they may also be cyclic ( g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl) or be linear or branched and contain cyclic moieties. Unless otherwise indicated, halogen includes fluorine, chlorine, bromine, and iodine.
(C2-Cj})Heterocycloalkyl when used herein refers to pyrrolidinyi, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyraπyl, aziridϊnyl, oxiraπyl, methylenedioxyl, chromenyl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thia2olidin-3-yl, 1 ,2-pyrazolidin-2-yt, 1,3-pyrazolidiπ-1-yl, piperidinyl, thiomorpholiπyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yI, tetrahydrothiadiazinyl, morpholinyl, 1 ,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-l- yl, tetrahydroazepinyl, piperaziπyl, chromanyl, etc. One of ordinary skill in the art will understand that the connection of said (Cz-Cg)heterocycloalkyl rings is through a carbon or a sp3 hybridized nitrogen heteroatom.
(C CgJHeteroaryl when used herein refers to furyl, thieπyl, thiazolyl, pyrazoiyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, i idazolyl, 1,3,5- oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,3,5-thϊadiazαlyl, 1,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyraziπyl, pyridazinyl, 1,2,4-triaziπyl, 1,2,3- triazinyl, 1 ,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7- dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5, 6, 7, 8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indoliziπyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazinyl; etc. One of ordinary skill in the art will understand that the connection of said (CjrCjjJheterocycloalkyl rings is through a carbon atom or a sp3 hybridized nitrogen heteroatom. (C6-C10)aryl when used herein refers to phenyl or naphthyl.
The compounds used in this invention include all conformational isαmers (e.g., cis and trans isomers. The compounds used in present invention have asymmetric centers and are therefore chiral and exist in different enantiomeric and diastereomeric forms. This invention relates to the resolution of optical isomers and stereoisomers of the precursors of constituents and thereby compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment that may employ or contain them. In this regard, the invention includes both the E and 2 configurations. The compounds of formula I may also exist as tautomers. This invention relates to such tautomers and mixtures thereof. In particular, resolution of racemic mixtures of enantiomers of compounds, used in providing the R1 substituent of formula I, is effected by treating the racemic mixture with a specific optical isomer of a disubstituted tartaric acid or tartrate in an appropriate solvent such as ethanol with or without water as a co-solvent. Resolution in obtaining the desired enantiomer in excess of 90% is possible in accordance with the method of the present invention with the use of resolving agents such as the optical isomers of tartaric acid and tartaric acid derivatives such as di-p-toluoyl- -tartaric acid and (S)-(+)-Andeno acid (pencyphos, (S)-(+)-2- hydroxy-5,5-dimethyl-4-pheπyl-1,3,2-dioxyphosphorinane-2-oxide) salt.. Interaction between antipodes of the resolving material and specific enantiomer provides a resolution of the racemic mixture whereby a precipitate of the resolving material and enantiomer provides one of the desired stereospecific materials and wherein the remaining eπaπtiometer in solution can be separately isolated thereby. Thus, depending on the specific enantiomer desired and the separation method to be used (i.e., from precipitate or solution), the stereospecific nature of the resolving nature can be concomitantly selected; e.g, an "L" form of the resolving agent such as a tartrate derivative provides a precipitate of an "R" form of the R1 substituent and a solution containing the "L" form and vice versa.
The aforementioned resolving agents are effective in providing a 3R.4R enantiomer of the compound of the formula (either in precipitate or solution, as described):
Figure imgf000008_0001
In accordance with the present invention the method of resolution of the compound of formula III is effected by the steps of: a) mixing a racemic mixture of the compound of formula III in an appropriate solution with a resolving compound, having a defined stereospecificity, for a time sufficient to allow substantial precipitation of a stereospecific isomer of the racemic mixture from the solution; b) depending on the stereospecific form of the compound which is desired, collecting either the precipitate and purifying it or collecting the mother liquor and recrystallizing the enantiomer contained therein.
With some materials a slurry rather that a solution is formed with the resolution of the present invention involving a slurry to slurry conversion. The term "solution" encompasses both a solution and a slurry.
The temperature at which the resolution and precipitation is effected is preferably ambient temperature and while precipitation time is not restricted for efficicency the time is preferably no more than about four hours. In order to facilitate the resolution it is desirable to use enantiomers in the racemic mixture which are in a stable form and the compound of formula II is most stable in acid addition salt form such as a hydrochloride salt, rather than a free base form and it is preferred that the racemic compound mixture be accordingly converted prior to resolution. Thus, for example, formation of the hydrochloride salt of the compound of formula II is effected preferably in ethanol with a small amount of toluene as cosolvent. Alternatively, methaπol, isopropaπol, acetonitrile, or tetrahydrofuran (or mixtures thereof with or without water as a cosolvent) with cosolvents of toluene, ethylacetate. dichloromethaπe, dichloroethane, or tetrahydrofuran may be used in the salt formation. The HCl salt is particularly preferred since this form provides a superior purification and enriched of other stereomers from the prior step.
A preferred displacement solvent to be used in the resolution is ethyl acetate. Toluene, acetonitrile, or heptanes are also useful as solvents. A preferred isolation solvent is acetone. Other solvents useful in this regard include isopropanol, ethanol, methyl ethyl ketone, methyl isopropyl ketone, acetonitrile, and tetrahydrofuran. The solvents may also be used as co-solvents with each other or with water.
Preferred resolution compounds include tartaric acid and its derivatives such as toluoyl and benzoyl tartaric acids in stereospecific conformation, as described. Other resolution compounds include spereospecific adeno acid and derivatives thereof.
To facilitate precipitation and recrystalization addition of seeds is optional, but preferred in order to obtain higher ee material with fewer recrystalizations. In order to illustrate the procedure and efficacy of the present invention the following examples are presented. It is understood that such examples are details contained therein are not to be construed as limitations on the present invention.
The present invention also relates to a method for preparing the compound of the formula
Figure imgf000010_0001
or the pharmaceutically acceptable salt thereof; wherein R1 is a group of the formula
Figure imgf000010_0002
wherein y is 0, 1 or 2;
R* is selected from the group consisting of hydrogen, (d-C6)alkyl, (d- C6)alkylsulfonyl, (C2-C6)alkeπyl, (C2-C6)alkynyl wherein the alkyl, alkenyl and alkynyl groups are optionally substituted by deuterium, hydroxy, amino, trifluoromethyl. (Ci- C4)alkoχy, (d-d acyloxy, (d-CeJalkylamino, ((C C6)alkyl)zamiπo, cyano, nitro, (C2-Cβ)alkenyl, (C2-CB)alkynyl or (C CB)acylamino; or R4 is (C3-C10)cycloalkyl wherein the cycloalkyl group is optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (d-C6)acyloxy, (d-CB)acylamiπo, (C CB)alkylamino, ((d- C6)alkyl)2amiho, cyano, cyano(Cι-C6)alkyl, trifluoromethyl(CrCe)alkyl, nitro, nitro(C C6)alkyl or (d-CB)acylamino; R5 is (CrCgJheterocycloalkyl wherein the heterαcyclαalkyl groups must be substituted by one to five carboxy, cyano, amino, deuterium, hydroxy, (CrCs)alkyl, (Cι-C6)alkoxy, halo, (CrCβ)acyt, (d-C6)alkylamiπo, amiπo(d-C6)alkyl, (C C6)alkoxy-CO-NH, (CrCB)alkylamino-CQ-, {C2-C3)alkenyl, (C2-C6) alkynyl, (Cr C6)alkylamino, amino(C C6)alkyl, hydroxy(CrCs)alkyl, (d-Cβ)alkαxy(CrCβ)alkyl, (d-C6)acyloxy(C Cβ)alkyl, nitro, cyano(d-Ce)alkyl, halo(C C6)alkyl, nitro(C C6)alkyl, trifluoromethyl, trifluoromethyl(d-C6)a(kyl, (C C6)acylamino, (C C6)acylamino(C Cs)alkyl, (d-C6)alkoxy(CrC6)acylamino, amino(Cι-C6)acyl, amino(C1-Ce)acyl(C1-CB)alkyl, (d-C6)alkylamino(CrC6)acyl, ((C
C6)alkyl)2amiπύ(C C6)acyl, R15R BN-CO-0-, R1sR1sN-C -(d-C6)alkyl, (C C6)alkyl- S(0)m, R 5R16NS(0)m, R15R16N$(0)m (d-C6)alkyl, R15S(0)m R1βN, R15S(0)mR16N(d- Cs)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (d-Ce)alkyl; or a group of the formula II
Figure imgf000011_0001
wherein a is 0, 1, 2, 3 or 4; b, c, e, f and g are each independently 0 or 1; d is O, 1, 2, or 3; X is S(0)n wherein n is 0, 1 or 2; oxygen, carbonyl or -C(=N-cyano)-;
Y is S(0)n wherein n is 0, 1 or 2; or carbonyl; and
Z is carbonyl, C(0)0-, C(0)NR- or S(0)„ wherein n is 0„1 or 2;
Rs, R7, Rs, R3, R10 and R11 are each independently selected from the group consisting of hydrogen or (d-Ce)alkyI optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (d-C6)acyloxy, (Cι-C6)acylamino, (CτC6)alkylamino, ((C
C6)alkyl)2amino, cyano, cyano(C1-C6)alkyl, trifluoromethy d-Ce alkyl, nitro, nitro(Cι-Ce)alkyl or (d-Ce)acylamino;
R12 is carboxy, cyano, amino. oxo, deuterium, hydroxy, trifluoromethyl, (CrCB)alkyl, trifluoromethyl(CrC6)aIkyl, (d-C6)alkoxy, halo, (d-C6)acyl, (Cι-C6)alkylamino, ((C C6)alkyl)2 amino, amino(C1-C6)alkyl, (CrC6)alkoxy-CO-NH, (d-Cs)alkylamino-CO-,
(C2-CB)alkenyl, (Crd) alkynyl, (CrC6)alkylamino, hydroxy(C C6)alkyl, (Cr
C6)alkoxy(C1-CB)alkyl, (C CB)acyloxy(C C6)alkyl, nitro, cyano(CrC6)alkyl, halo(d-
C6)alkyl, nitro(C Ce)aikyl, trifluoromethyl, trifluoromethyl(CrC6)alkyl, (d-
C6)acylarnino, (d-Ce)acylamino(C,-CB)alkyl, (CrC6)alkoxy(C C6)acylamino, amiπo(C1-Ce)acyl, amino(Cτd)acyl(CrC6)alkyl. (Cl-CB)alkylamino(C1-C6)acy], ((Cr
C6)alkyl)2amino(C1-C6)acyl, R 5R1$N-CO-0^, RlSR1BN-CO-(d-Cβ)alkyl, R15C(0)NH,
R 5OC(0)NH, R1SNHC(0)NH, (CrCβ)alkyl-S(0)m, (CrC6)alkyl-S(0)m-(d-C6)alkyl,
R15R16NS(0)m, R1sRl6NS(0)m (d-Ce)alkyl, R 5S(0)m R1BN, R15S(0)mR16N(d-Cβ)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (CrC6)alkyl;
R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, amino, halo, hydoxy, nitro, carboxy, (C2-C6)alkenyl, (Cr CB)alkynyl, trifluoromethyl, trifluoromethoxy, (C1-CB)alkyl, (d-C6)alkoxy, (C3- Cιo)cycloalkyl wherein the alkyl, alkoxy or cycloalkyl groups are optionally substittued by one to three groups selected from halo, hydroxy, carboxy, amino (d-C6)alkylthio, (Cι-C6)alkylamino, ((d-C6)alkyl)2amino, (C5-C8)heteroaryl, (C2-C8)heterocycloalkyl, (C3-C$)cycloalkyl or (Cβ-d0)aryl; or R2 and R3 are each independently (C3- Cιo)cycloalkyl, (C -C10)cycloalkoxy, (d-C6)alkylamino, ((CrC6)alkyl)2amino, (Ce- C1Q)arylamiπo, (CrC6)alkylthio, (C6-C10)arylthio. (CrCB)alkylsulfinyl, (C6- C10)arylsulfιnyl, (C C6)aIkylsulfonyl, (CB-C10)arylsulfonyl, (C C6)acyl, (C CB)alkoxy- CO-NH-, (d-C6)alkyamino-CO-, (QrCgJheteroaryf, (C2-C9)heterocycloalkyl or (Ce- C10)aryl wherein the heteroaryl, heterocycloalkyl and aryl groups are optionally substituted by one to three halo, (C C6)alkyl, (d-CB)alkyl-CO-NH-, (CrCβ)alkoxy- CO-NH-, (C Cβ)alkyl-CO-NH-(CrCβ)alkyl, (Cv-C6)alkoxy-CO-NH-(C C6)alkyl, (Cr C6)alkoxy-CO-NH-(C1-C6)alkoxy, carboxy, carboxy(C Ca)alkyl, carboxy(Cι-C6)alkoxy, benzyloxycarboπyl(C C6)alkoxy, (d-CsJalkoxycarboπy^d-CβJalkoxy, (Ce-C10)aryl, amino, amino(CrC6)alkyl, (d-Ce)alkoxycarbonylamino, (C6-Cιo)aryl(d- Ce)alkoxycarbonylamiπo, (d-Cβ)alkylamino, ((CrCe)alkyl)2amino, (Cr
Cβ)alkylamino(C1-C6)alkyl, ((Cι-C6)alkyl)2amϊno(CrC6)alkyl, hydroxy, (d-C6)alkoxy, carboxy, carboxy(CrC6)alkyl, (CrCB)alkθxycarboπyl, (CrC6)alkoxycarbonyl(C C6)alkyl, (Cι-C6)alkoxy-CO-NH-, (CrC6)alkyl-CO-NH-, cyano, (C5-C9)heterocycloalkyl, amino-CO-NH-, (CrCβ)alkylamino-CO-NH-, ((C1-C6)alkyl)2amino-CO-NH-, (C6- C10)arylamiπo-CO-NH-, (C3-C )heteroarylamino-CO-NH-, (C C6)alkylamiπo-CO-NH- (CrC6)alkyl, ((d-CβJalkyl^amino-CO-NH-fC CsJalkyl, (C6-C10)arylamino-CO-NH-(C1- Cs)alkyl, (C3-Cg)heteroarylamino-CO"NH-(C1-C6)alkyl, (CrC6)alkylsulfonyl, (C Cs)alkylsulfonylamino, (CrCB)alkylsulfonylamino(d-C6)alkyl, (Ce-do)arylsulfonyl, (Ce- C10)arylsulfonylamino, (C6-C10)arylsuIfonylamino(C C6)alkyl, (C C6)alkylsulfonylamino, (d-C6)alkylsulfonylamino(Cι-Cβ)alkyl, (Cε-Cgjheteroaryl or (Cr CB)heterocycloalkyl; said method comprising the steps of: a) mixing a racemic mixture of enantiomeric compounds of the formula
R NΛCH2)y
H wherein y, R4 and R5 are as defined above, in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with said resolving agent being capable of binding with at least one but not all of said enantiomers to form a precipitate, containing said at least one of said enantiomers, b) allowing the mixture to stand for a time sufficient to allow substantial precipitation of a stereospecific enantiomer of the racemic mixture from the solution and wherein another of said enantiomers remains in said solution; c) depending on the stereospecific enantiomer of the compound which is desired, collecting either the precipitate and purifying it or collecting the solution with contained other of said enantiomers and recrystalliziπg the enantiomer contained in said solution; and d) reacting the desired stereospecific enantiomer so formed with a compound of the formula
Figure imgf000013_0001
wherein R is hydrogen or a protecting group and R2 and R3 are as defined above. The present invention also relates to a compound of the formula
Figure imgf000013_0002
Wherein R2 and Ra are each independently selected from the group consisting of hydrogen, deuterium, amino, halo, hydoxy, nitro, carboxy, (C2- C6)alkenyl, (C2-Ce)alkynyl, trifluoromethyl, trifluoromethoxy, (d-Cβ)alkyl, (C C6)alkoxy, (C3-Cl0)cycloalkyl wherein the alkyl, alkoxy or cycloalkyl groups are optionally substittued by one to three groups selected from halo, hydroxy, carboxy, amino (d-Ce)alkylthio, (d-Cβ)alkylamino, ((d-C6)alkyl)2amino, (C5-Cg)heteroaryl, (C2-C9)heterocycloalkyl, (C3-C9)cycloalkyl or (CB-C10)aryl; or R2 and 3 are each independently (C3-C10)cycloalkyl, (C3-C10)cycloalkoxy, (d-CβJalkylamino, ((Cr C$)alkyl)2amino, (Ce-C10)arylamϊπo, (C C6)alkylthio, (C6-C10)arylthio, (Cr Ce)alkylsulfinyl, (Cβ-C,0)arylsulfinyl, (C Ce)alkylsulfonyl, (C -C1D)arylsulfonyl, (Cr C6)acyl, (C CB)alkoxy-CO-NH-, (CrC6)alkyamino-CO-, (C5-C9)heteroaryl, (C2- Cg)heterocycloalkyl or (C6-Cι0)aryl wherein the heteroaryl, heterocycloalkyl and aryl groups are optionally substituted by one to three halo, (Cι-C$)alkyl, (d-C6)alkyl-CO- NH-, (C C6)alkoxy-CO-NH-, (C C6)alkyl-CO-NH-(d-Cβ)alkyl, (CrC6)alkoxy-CO- NH-(CrCe)alkyl, (C1-C6)alkoχy-CO-NH-(C1-C6)alkoxy, carboxy, carboxy(C C6)alkyl, carboxy(Cι-CB)alkoxy, benzyloxycarbonyl(C CB)alkαxy, (C CB)alkoxycarbonyl(C CB)alkoxy, (C6-Cι0)aryl, amino, amino(d-C6)alkyl, (d-Cβ)alkoxycarbonylamino, (C6- CioJary C CβJalkoxycarbonylamino, (C C6)alkylamino, ((C CB)alkyl)2amino, (C Ce)alkylamino(d-Ce)alkyl, (( -CβJalky jaminoC -CβJal yl, hydroxy, (d-djalkoxy, carboxy, carboxy(CrC6)alkyl, (Cι-Cε)alkoxycarbonyl, (Cι-C3)alkoxycarbonyi{d- C6)alkyl, (C CB)alkoxy-CO-NH-, (d-Cβ)alkyl-CO-NH-, cyano, (C3- Cg)heterocycloalkyl, amino-CO-NH-, (CrC6)alkylamino-CO-NH-, ((d- C6)alkyl)2amino-CO-NH-, (C6-C1Q)arylamino-CO-NH-, (Cs-Cg)heteroarylamino-CO- NH-, (d-C6)alkylamino-CO-NH-(d-C6)alkyl, ((CrC6)alkyl)2amino-CO-NH-(C C6)alkyl, (Cs-doJarylamino-CO-NH- d-CeJalkyl, (C5-C9)heteroarylamino-CO-NH- (C C6)alkyl, (C C6)alkylsulfonyl, (d-CeJalkylsulfonylamino, (C
CeJalkylsulfonylamiπofC^CeJalkyl, (C6-C10)arylsuifonyl, (C6-C 0)arylsulfonylamino, (Cβ-do)arylsulfonylamino(d-CB)alkyl, (Cι-Ce)alkylsulfoπylamino, (Cr
C6)alkylsulfonylamino(C C6)alkyl, (C5-C9)heteroaryl or (C Cg)heterocycloalkyl.
The present invention also relates to specifically preferred compounds selected from the group consisting of:
Methyl-[(3R,4R)-4-methyl-1-(propane-1-su|fonyl)-pipeήdin-3-yQ-(7H- pyrrolo{2,3-d]pyrimidin-4-yl)-amine;
(3R,4R)-)-4-Methyl-3-|;methyl-(7H-ρyrrolo[213-d]pyrimidin- -yl)-amiπo]- piperidine-1 -carboxylic acid methyl ester; 3,3,3-Trifluoro-H(3R)4R)-4-methyl-3-[methyl-(7H-pyrrolo[2)3-d]pyrimidin-4- yl)-amino]-piperidin-1 -yl}-propan-1 -one;
(3R,4R)- -Methyl"3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]- piperidine-1 -carboxylic acid dimethylamide; {(3R,4RH-Methyl-3-[methyl-(7H-pyrrolo[2,3-d}pyrimidin-4-yl)-amino)- piperidine-1-carbonyl}-amino acetic acid ethyl ester,
3-{(3R,4R)-4- et'hyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-aminoJ- piperidin-l-yl}-3-oxo-prapionitrile; 3,3,3-Trifluoro-H(3R,4R)-4-methyl-3-[methyl-(5-methyl-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-amino]-piperidin- 1 -yl}-propan-1 -one;
H(3R,4R)-4-Methyl-3-|;methyl-(7H-ρyrrolo[2)3-d]pyrimidin- -yI)-amino]- piperidin-1 -yl}-but-3-yπ-1 -one;
1-{(3R,4R)-3-[(5-Chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl'amino) - methyl-ρiperidin-1 -yl}-propan-1 -one;
H(3R,4R)-3-[(5-Fiuoro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl-amino3- - methyl-piperidin-1-yl}-propan-1-one;
(3R,4R -N-cyano-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin- -yl)-amiπo]- N'-propyl-piperidine-1 -carboxamidine; and (SR^RJ-N-cyaπo^.N^N'-Trimethyl-S-tmethyl-r H-pyrrolop^-dJpyrimidin^yl)- amino]-piperidine-1-carboxamidine.
The present invention also relates to a pharmaceutical composition for (a) treating or preventing a disorder or condition selected from organ transplant rejection, xeno translation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia, and other autoimmune diseases or (b) the inhibition of protein kinases or Janus Kinase 3 (JAK3) in a mammal, including a human, comprising an amount of an above described specifically preferred compound or a pharmaceutically acceptable salt thereof, effective in such disorders or conditions and a pharmaceutically acceptable carrier.
The present invention also relates to a method for the inhibition of protein typrosine kinases or Janus Kinase 3 (JAK3) in a mammal, including a human, comprising administering to said mammal an effective amount of an above described specifically preferred compound or a pharmaceutically acceptable salt thereof.
The present invention also relates to a method for treating or preventing a disorder or condition selected from organ transplant rejection, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis. Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia, and other autoimmune diseases in a mammal, including a human, comprising administering to said mammal an amount of an above described specifically preferred compound or a pharmaceutically acceptable salt thereof, effective in treating such a condition.
The present invention also relates to a compound of the formula
Figure imgf000016_0001
The present invention also relates to a compound of the formula
Figure imgf000016_0002
The present invention also relates to a compound of the formula
Figure imgf000016_0003
Detailed Description of the Invention The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated R2, R3, R4 and R5 in the reaction Schemes and the discussion that follow are defined as above. PREPARATION A
Figure imgf000017_0001
PREPARATION B
Figure imgf000018_0001
Figure imgf000018_0002
Figure imgf000018_0003
SCHEME 1
Figure imgf000019_0001
Figure imgf000019_0002
Figure imgf000019_0003
SCHEME 2
Figure imgf000020_0001
III
Figure imgf000020_0002
SCHEME 3
Figure imgf000021_0001
Figure imgf000021_0002
In reaction 1 of Preparation A, the 4-chIoropyrrolo[2,3-d]pyrimidine compound of formula XXI, wherein R is hydrogen or a protecting group such as benzenesulfonyl or benzyl, is converted to the 4-chloro-5-halopyrrolo[2,3-d]pyrimidine compound of formula XX, wherein Y is chloro, bromo or iodo, by reacting XXI with N- chlorosuccinimide, N-bromosuccinimide or N-iodosucciπimide. The reaction mixture is heated to reflux, in chloroform, for a time period between about 1 hour to about 3 hours, preferably about 1 hour. Alternatively, in reaction 1 of Preparation A, the 4- chloropyrrolo[2,3-d]pyrimidine of formula XXI, wherein R is hydrogen, is converted to the corresponding 4-chloro-5-n"ιtropyrrolo[2,3-d]pyrimidiπe of formula XX, wherein Y is nitro, by reacting XXI with nitric acid in sulfuric acid at a temperature between about - 10όC to about 10°C, preferably about 0°C, for a time period between about 5 minutes to about 15 minutes, preferably about 10 minutes. The compound of formula XXI, wherein Y is nitro, is converted to the corresponding 4-chlpro-5-aminopyrrolo[2,3- djpyrimidine of the formula XX, wherein Y is amino, by reacting XXI under a variety of conditions known to one skilled in the art such as palladium hydrogenolysis or tin(IV)chloride and hydrochloric acid.
In reaction 2 of Preparation A, the 4-chloro-5-halopyrrolo(2,3-d]pyrimidine compound of formula XX, wherein R is hydrogen, is converted to the corresponding compound of formula XIX, wherein R2 is (Cι-C6)alkyl or benzyl, by treating XX with N- butyllithium, at a temperature of about ~78°C, and reacting the dianion intermediate so formed with an alkylhalide or beπzylhalide at a temperature between about -78°C to room temperature, preferably room temperature. Alternatively, the dianion so formed is reacted with molecular oxygen to form the corresponding 4-chlorc-5- hydroxypyrrolo[2,3-d]pyrimidine compound of formula XIX, wherein R2 is hydroxy. The compound of formula XX, wherein Y is bromine or iodine and R is benzenesulfonate, is converted to the compound of formula XIX, herein R2 is (Cβ- C12)aryl or vinyl, by treating XX with N-butyllithium, at a temperature of about -78°C, followed by the addition of zinc chloride, at a temperature of about -78"C. The corresponding organo zinc intermediate so formed is then reacted with aryliodide or vinyl iodide in the presence of a catalytic quantity of palladium. The reaction mixture is stirred at a temperature between about 50°C to about 80°C, preferably about 70°C, for a time period between about 1 hour to about 3 hours, preferably about 1 hour.
In reaction 3 of Preparation A, the compound of formula XIX is converted to the corresponding compound of formula XVI by treating XIX with N-butyllithium, lithium diisopropylamiπe or sodium hydride, at a temperature of about -78°C, in the presence of a polar aprotic solvent, such as tetrahydrofuran. The anionic intermediate so formed is further reacted with (a) alkylhalide or benzylhalide, at a temperature between about -78°C to room temperature, preferably -78 °C, when R3 is alkyl or benzyl; (b) an aldehyde or ketone, at a temperature between about -78βC to room temperature, preferably -78°C, when R3 is alkoxy; and (c) zinc chloride, at a temperature between about -78°C to room temperature, preferably -78°C, and the corresponding organozinc intermediate so formed is then reacted with aryliqdide or vinyl iodide in the presence of a catalytic quantity of palladium. The resulting reaction mixture is stirred at a temperature between about 50 C to about 80°C, preferably about 70°C, for a time period between about 1 hour to about 3 hours, preferably about 1 hour. Alternatively, the anion so formed is reacted with molecular oxygen to form the corresponding 4-chloro-6-hydroxypyrrolo[2,3-d]pyrimidiπe compound of formula XVI, wherein R3 is hydroxy. In reaction 1 of Preparation E, the 4-chloropyrrolo[2,3-dJpyrimidine compound of formula XXI is converted to the corresponding compound of formula XXII, according to the procedure described above in reaction 3 of Preparation A,
In reaction 2 of Preparation B, the compound of formula XXII is converted to the corresponding compound of formula XVI, according to the procedures described above in reactions 1 and 2 of Preparation A.
In reaction 1 of Scheme 1, the 4-chloropyιτolo[2,3-dJpyrimidine compound of formula XVII is converted to the corresponding compound of formula XVI, wherein R is benzenesulfonyl or benzyl, by treating XVII with benzenesulfonyl chloride, benzylchloride or benzylbromide in the presence of a base, such as sodium hydride or potassium carbonate, and a polar aprotic solvent, such as dimethylformamide or tetrahydrofuran. The reaction mixture is stirred at a temperature between about 0°C to about 70°C, preferably about 30°C, for a time period between about 1 hour to about 3 hours, preferably about 2 hours.
In reaction 2 of Scheme r the 4-chloropyrrolo[2,3-d]pyrimidine compound of formula XVI is converted to the corresponding 4-aminopyrroIo[213-d]pyrimidine compound of formula XV by coupling XVI with an amine of the formula HNR RS. The reaction is carried out in water or an alcohol solvent, such as tert-butanol, methanol or ethanol, or other high boiling organic solvents, such as dimethylformamide, triethylamine, 1,4-dioxane or 1 ,2-dichloroethane, at a temperature between about 60°C to about 120°C, preferably about 80°C. Typical reaction times are between about 2 hours to about 100 hours, preferably about 48 hours. When Rs is a nitrogen containing heterocycloalkyl group, each nitrogen must be protected by a protecting group, such a benzyl. Removal of the R5 protecting group is carried out under conditions appropriate for that particular protecting group in use which will not affect the R protecting group on the pyrrolo[2,3-d]pyrimidine ring. Removal of the Rs protecting group, when benzyl, is carried out in an alcohol solvent, such as ethanol, in the present of hydrogen and a catalyst, such as palladium hydroxide on carbon, at temperatures ranging from room temperature to about 70βC. The R5 nitrogen containing hetrocycloalkyl group so formed may be further reacted with a variety of different electrophiles of formula II. For urea formation, electrophiles of formula II such as isocyanates, carbamates and carbamoyl chlorides are reacted with the R5 nitrogen of the heteroalkyl group in a solvent, such as acetonitrile or dimethylformamide, in the presence of a base, such as sodium or potassium carbonate, at a temperature between about 20°C to about 100 °C for a time period between about 24 hours to about 72 hours. For amide and sulfonamide formation, electrophiles of formula II, such as acylchlαrides and sulfoπyl chlorides, are reacted with the R5 nitrogen of the heteroalkyl group in a solvent such as methylene chloride in the presence of a base such as pyridine at ambient temperatures for a time period between about 12 hours to about 24 hours. Amide formation may also be carried out by reacting a carboxylic acid with the heteroalkyl group in the presence of a carbodiimide such as 1-(3-dimethylaminopropyl)-3-ethyicarbodiimide in a solvent such as methylene chloride at ambient temperatures for about 12 to about 24 hours, or with an activated ester, such as N-hydroxysuccinimide ester, or 4-nitrophenyl ester in a solvent such as methylene chloride, tetrahydrofuran or ethanol. For alkyl formation, electrophiles of formula II, such as α,β-unsatu rated amides, acids, nitriles, esters, and α-halo amides, are reacted with the R$ nitrogen of the heteroalkyl group in a solvent such as methanol at ambient temperatures for a time period between about 12 hours to about 18 hours. Alkyl formation may also be carried out by reacting aldehydes with the heteroalkyl group in the presence of a reducing agent, such as sodium cyaπoborohydride, in a solvent, such as methanol, at ambient temperature for a time period between about 12 hours to about 18 hours.
In reaction 3 of Scheme 1, removal of the protecting group from the compound of formula XV, wherein R is benzenesulfonyl, to give the corresponding compound of formula I, is carried out by treating XV with an alkali base, such as sodium hydroxide or potassium hydroxide, in an alcohol solvent, such as methanol or ethanol, or mixed solvents, such as alcαhol/tetrahydrofuran or alcohol/water. The reaction is carried out at room temperature for a time period between about 15 minutes to about 1 hour, preferably 30 minutes. Removal of the protecting group from the compound of formula XV, wherein R is benzyl, is conducted by treating XV with sodium in ammonia at a temperature of about -78°C for a time period between about 15 minutes to about 1 hour.
In reaction 1 of Scheme 2, the 4-chloropyrrolo[2,3-d]pyrimidine compound of formula XX is converted to the corresponding 4-aminopyrrolo[2,3-d]pyrimidine compound of formula XXIV, according to the procedure described above in reaction 2 of Scheme JL
In reaction 2 of Scheme 2, the 4-amino-5-halopyrrolo[2,3-d]pyrimidine compound of formula XXIV, wherein R is benzenesulfonate and Z is bromine or iodine, is converted to the corresponding compound of formula XXIII by reacting XXIV with (a) arylboronic a d, when R2 is aryl, in an aprotic solvent, such tetrahydrofuran or dioxane, in the presence of a catalytic quantity of palladium (0) at a temperature between about 50όC to about 100PC, preferably about 70°C, for a time period between about 2 hours to about 48 hours, preferably about 12 hours; (b) alkyπes, when R2 is alkynyl, in the presence of a catalytic quantity of copper (I) iodide and palladium (0), and a polar solvent, such as dimethylformamide, at room temperature, for a time period between about 1 hour to about 5 hours, preferably about 3 hours; and (c) alkenes or styreπes, when R2 is vinyl or styrenyl, in the presence of a catalytic quantity of palladium in dimethylformamide, dioxane or tetrahydrofuran, at a temperature between about 80°C to about 100°C, preferably about 100°C, for a time period between about 2 hours to about 48 hours, preferably about 48 hours.
In reaction 3 of Scheme 2, the compound of formula XXIII is converted to the corresponding compound of formula XV, according to the procedure described above in reaction 3 of Preparation A. In reaction 1 of Scheme 3, the compound of formula XVII is converted to the corresponding compound of formula I, according to the procedure described above in reaction 2 of Scheme Λ_.
The compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction, mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as acetone, methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
Those compounds of the present invention that are acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the calcium, sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product. The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation. The active compounds of the invention may also be formulated for sustained delivery.
For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatϊnized maize starch, polyvinylpyrrolidoπe or hydroxypropyl methylcellulose); fillers (e.g.. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g.. potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g.. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g.. methyl or propyl p-hydroxybeπzoates or sσrbic acid).
For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner. The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, §&., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g,.. sterile pyrogen-free water, before use. The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g.. containing conventional suppository bases such as cocoa butter or other glycerides.
For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e^., dichlorodifluoromethaπe, trichlσrofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
A proposed dose of the active compounds of the invention for oral, parenteral ar buccal administration to the average adult human for the treatment of the conditions referred to above (e.g.. rheumatoid arthritis) is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
Aerosol formulations for treatment of the conditions referred to above (e.g.. asthma) in the average adult human are preferably arranged so that each metered dose or "puff of aerosol contains 20 μg to 1000 μg of the compound of the invention. The overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1 , 2 or 3 doses each time. A compound of formula (I) administered in a pharmaceutically acceptable form either alone or in combination with one or more additional agents which modulate a mammlian immune system, or with antiinflammatory agents, agents which may include but are not limited to cyclosporin A (e.g. Sandimmune® or Neoral®, rapamycin, FK-506 (tacrolimus), leflunomide, deoxyspergualin, mycophenolate (e.g. Cellcept®, azathioprine (e.g. Imuran®), daclizumab (e.g. Zenapax®), OKT3 (e.g. Orthocolone®), AtGam, aspirin, acetaminophen, ibuprofen, naproxen, piroxicam, and aπtiinflmmatory steroids (e.g. prednisolone or dexamethasone); and such agents may be administered as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical practice.
FK506 (Tacrolimus) is given orally at 0.10-0.15 mg/kg body weight, every 12 hours, within first 48 hours postoperative. Does is monitored by serum Tacrolimus trough levels. Cyclosporiπ A (Sandimmune oral or intravenous formulation, or Neoral®, oral solution or capsules) is given orally at 5 mg/kg body weight, every 12 hours within 48 hours postoperative. Dose is monitored by blood Cyclosporin A trough levels.
The active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in United States Patents 3,538,214, 4,060,598, 4,173,626, 3,119,742, and 3,492,397.
The ability of the compounds of formula I or their pharmaceutically acceptable salts to inhibit Janus Kinase 3 and, consequently, demonstrate their effectiveness for treating disorders or conditions characterized by Janus Kinase 3 is shown by the following in vitro assay tests.
Biological Assay JAK3 fJH1:GST) Enzymatic Assay The JAK3 kinase assay utilizes a protein expressed in baculovirus-iπfected SF9 cells (a fusion protein of GST and the catalytic domain of human JAK3) purified by affinity chromatography on glutathione-Sepaharose. The substrate for the reaction is poly-Glutamic acid- yrosine (PGT (4:1), Sigma catalog # P0275), coated onto Nuπc Maxi Sorp plates at 100 μg/ml overnight at 37°C. The morning after coating, the plates are washed three times and JAK3 is added to the wells containing 100 μl of kinase buffer (50 mM HEPES, pH 7.3, 125 M NaCl, 24 M MgCI2)+ 0,2 uM ATP + 1 mM Na orthovanadate.) The reaction proceeds for 30 minutes at room temperature and the plates is washed three more times. The level of phosphorylated tyrosine in a given well is quantitated by standard ELISA assay utilizing an anti- phosphotyrosine antibody (ICN PY20, cat. #69-151-1). Inhibition of Human )L-2 Dependent T-Cell Blast Proliferation
This screen measures the inhibitory effect of compounds on IL-2 dependent T-Cell blast proliferation in vitro. Since signaling through the IL-2 receptor requires JAK-3, cell active inhibitors of JAK-3 should inhibit IL-2 dependent T-Cell blast proliferation. The cells for this assay are isolated from fresh human blood. After separation of the mononuclear cells using Accuspin System-Histopaque-1077 (Sigma # A7054). primary human T-Cells are isolated by negative selection using Lympho-Kwik T (One Lambda, Inc., Cat # LK-50T). T-Cells are cultured at 1-2 x 10β/ml in Media (RPMI + 10% heat-inactivated fetal calf serum (Hyclone Cat # A-1111-L) + 1% Penicillin/Streptomycin (Gibco)) and induce to proliferate by the addition of 10ug/ml PHA (Murex Diagnostics, Cat # HA 16). After 3 days at 37°C in 5% C02, cells are washed 3 times in Media, resuspended to a density of 1-2 x 105 cells/ml in Media plus 100 Units/ml of human recombinant IL-2 (R&D Systems, Cat# 202-lL). After 1 week the cells are IL-2 dependent and can be maintained for up to 3 weeks by feeding twice weekly with equal volumes of Media + 100 Units/ml of IL-2.
To assay for a test compounds ability to inhibit IL-2 dependent T-Cell proliferation, IL-2 dependent cells are washed 3 times, resuspended in media and then plated (50,000 cells/well/0.1ml) in a Flat-bottom 96-well microtiter plate (Falcon # 353075). From a10 mM stock of test compound in DMSO, serial 2-fold dilutions of compound are added in triplicate wells starting at 10 uM. After one hour, 10 Units/ml of IL-2 is added to each test well. Plates are then incubated at 37°C, 5% CQ 2 for 72 hours. Plates are then pulsed with H-thymidine (0.5 uCi/well) (NEN Cat # NET- 027A), and incubated an additional 18 hours. Culture plates are then harvested with a 96-well plate harvester and the amount of 3H-thymidine incorporated into proliferating cells is determined by counting on a Packard Top Count scintillation counter. Data is analyzed by plotting the % inhibition of proliferation verses the concentration of test compound. An 1C50 value (uM) is determined from this plot,
The following Examples illustrate the preparation of the compounds of the present invention but it is not limited to the details thereof. Melting points are uπcorrected. NMR data are reported in parts per million (δ) and are referenced to the deuterium lock signal from the sample solvent (deuteriochloroform unless otherwise specified). Commercial reagents were utilized without further purification. THF refers to tetrahydrofuran. DMF refers to N.NHJirnethylformamide. Low Resolution Mass Spectra (LRMS) were recorded on either a Hewlett Packard 5989®, utilizing chemical ionization (ammonium), or a Fisons (or Micro Mass) Atmospheric Pressure Chemical Ionization (APCI) platform which uses a 50/50 mixture of acetonitrile/water with 0.1% formic acid as the ionizing agent. Room or ambient temperature refers to 20-25°C. EXAMPLE 1 (stable salt formation)
(1-benzyl-4-m6thylpiperidin-3-yl)-methylamine bishvdrochloride To a solution of 23.4kg of (1-benzyl-4-methylpiperidin-3-yl)-methylamine in 10 liters of toluene and 120 liters of ethanol at 3°C was added 25 liters of 32% HCl in water, keeping the reaction temperature below 10*C. 100 liters of solvent was distilled off under partial vacuum, and 215 liters of ethyl acetate was added at 30°C. 210 liters of solvent was distilled off under partial vacuum, and a second 215 liters of ethyl acetate was added and another 210 liters of solvent was distilled off under partial vacuum. 111 liters of acetone was added at 35C", the suspension was cooled to 0"C, and then the product, (1-beπzyl-4-methylpiperidϊn-3-yl)-methylamine bishydrochioride, was filtered off and washed with 55 liters of acetone. The wet-cake was reslurried 3 times in ethanol (10 volume equivalents at reflux) to upgrade the diasteromeric ratio of cis:trans from 91:9 to greater than 97:3; Total recovery was 19.4kg, 62% yield. 1H NMR (CDaOD, 400 MHz): 7.55 (m, 5H), 4.88 (s, 3H), 4.52 (d, J = 12.8 Hz, 1H), 4.45 (d, J = 12.8 Hz, 1H), 3.76 ( , IH), 3.67 (m, 1H), 3.40-3.00 (m. 3H), 2.78 (3, 3H), 2.55 (m, 1H), 2.14 (m, 1H), 1.90 (m. 1H), 1.16 (d, J = 7.2 Hz, 3H)
EXAMPLE 2 (resolution) bisr(1-benzyl- -methylpiperidin-3-yl):methylaminel di-py-toIuyl-L-tartrate To a solution of 9.5kg of (1-benzyl-4-methyIpiperidin-3-yl)-methylamine bishydrochioride in 16 liters of water was added 33 liters of 2N sodium hydroxide. Solids precipitated from the mixture. The slurry was diluted with 43 liters of isopropanol and 11 liters of methanol to redissolve the solids. Di-p-toluyl-L-tartaric acid (6.3kg) was added, with precipitation of solids. The slurry was heated to reflux to redissolve the solids, then slowly cooled to 72βC. Seeds of bis[(1-benzyl-4- methyIpiperidin-3-yl)-methylamine] di-p-toluyl-L-tartrate were added (180grams), and the hazy solution was slowly cooled to 15°C. The solids were filtered and washed with isopropanol to yield 5.9kg of bis[(1-benzyl-4-methylpiperidin-3-yl)- methylamine] di-p-toluyl-L-tartrate in 44% yield. 1H NMR (CD3OD, 400 MHz): 8.04 (d, J = 8.4 Hz, 2H), 7.30 (m, 7H), 5.86 (s, 1H), 4.91 (s, 3H), 3.64 (d, J = 12.8 Hz, 1H), 3.41 (d, J = 12.8 Hz, 1H), 3.09 (s, 1H), 2.90 (m, 2H), 2.40 (s, 3H), 2.22 (m, 2H), 1.92 (m, 1H), 1.57 (m, 2H), 1.03 (d, J = 7.2 Hz, 3H)
EXAMPLE 3 (phencyphos resolution) To a solution of 6.83 grams (31.3 mmol) in 250 ml IPA and 10 ml water was added 7.57 g (+) phencyphos (31.3 mmol), and the mixture was heated to reflux in order to obtain a clear solution. At a temperature of approximately 65° C seeding crystals with an ee of 90% were added. Crystallization started within one hour and the mixture was allowed to reach room temperature overnight Isolation afforded 6.85 g (47%) with an ee of 99%. The filtrate was concentrated, TBME, water and K2C03 were added, and the layers separated. The organic layer was dried (Na2S04)) and the solvent evaporated. The resulting oil (3.99 grams) was dissolved in 200 ml IPA and 10 ml water and 4.4 grams(-) phencyphos was added. The mixture was heated to reflux and allowed to cool to room temperature overnight. This afforded 6 grams (41%) salt with an ee of 99.9+% Analyses were performed on the free amine. The free amine was obtained by treatment of the salt with TBME, water and K2C03.
The following schematically illustrate the methods of Examples 1 to 3
(wherein Bn is defined as benzyl (-CHrdHs)):
Figure imgf000032_0001
racemic racemic
Figure imgf000032_0002
racemic
Figure imgf000032_0003
93%ee
Figure imgf000032_0004
EXAMPLE 4
A racemic mixture of the compound of formula 111 was resolved:
Figure imgf000033_0001
CP-673,881 ill Sample processing:
A compound of formula III was filtered through a 0.2 um nylon 66 filter disc. Procedure: (96% ethanol 4% water as solvent)
0.8711 grams of the compound of formula III, of the filtrate, was dissolved in
5.0 ml of a 96:4 ratio of ethanol/water, 1.544 grams of di-p-toluoyl-L-tartaric acid was added and the mixture was stirred to obtain a clear solution. The solution was allowed to stand at room temperature for approximately 4 hours. The resulting slurry was filtered onto Whatman #2 filter paper and washed with 4.0 ml of a 96:4 ratio of ethanol/water. The solids were air dried to give 0.488 grams of the diastereomer salt.
0.488 grams of the diastereomer salt was suspended in 50 ml of water then
50 ml of methylene chloride was added. The pH of the mixture was adjusted to approximately 9 using saturated sodium bicarbonate followed by 1.0N sodium hydroxide. Upon completion of the pH adjustment, the layers were separated and the methylene chloride layer was filtered through Whatman #2 filter paper. Solvents were then removed by reduced pressure evaporation to give a light orange colored oil. Weight not determined. This oil was evaluated by gas chromatαgraphy.
Analytical assay: 97.3% desired enantiomer by normalized area percent. EXAMPLE 5
Procedure: (100% ethanol as solvent)
0.8714 grams of (1-benzyl-4~methyl-piperidin-3-yl)-methyl-amine was dissolved in 5.0 ml of 200 proof ethanol. 1.544 grams of di-p-toluoyl-L-tartaric acid was added and the mixture was stirred to obtain a clear solution. The solution was allowed to stand at room temperature for approximately 4 hours. The resulting slurry was filtered onto Whatman #2 filter paper and washed with 4.0 ml of a 96:4 ratio of ethanol/water. The solids were air dried to give 0.628 grams of the diastereomer salt. 0.628 grams of the diastereomer salt was suspended in 50 ml of water then 50 ml of methylene chloride was added. The pH of the mixture was adjusted to approximately 9 using saturated sodium bicarbonate followed by 0.1N sodium hydroxide. Upon completion of the pH adjustment, the layers were separated and the methylene chloride layer was filtered through Whatman #2 filter paper. Solvents were then removed by reduced pressure evaporation to give a light yellow colored oil. Weight not determined. Evaluation of the oil provided the analytical assay; 90.5% desired enantiomer by normalized area percent.
EXAMPLE 6
3-f(3R, 4R)-4-Methyl-3-rmβthyl-(7H-pγrrolor2,3-d1pyrimi in- «yl)-amirιo1- pi peridiπ-1 -yl}'3-oxo-propi on itrile
Method A (3R.4R)-(1-Ben2Vl-4-methyl-piperidin-3-yl)>methyl-(7H-pyrrolof2.3"dlPyrimidin-
4-yl)-aminβ
4-Chloropyrrolo[2,3-o pyrimidine (5.37 grams, 34.9 mmol), prepared by the method of Davoll, J. Am. Chem. Soc, 82, 131 (1960), which is incorporated by reference in its entirety, the product from Example 2 (6 grams, 27.5 mmol) and potassium carbonate (11.4 grams, 82.5 mmol) were combined in water (60 ml). The slurry was heated at reflux for 90 hrs. The mixture was cooled to 90°C and toluene
(60 ml) was added. The biphasic mixture was filtered through filter aid and the layers were separated. The aqueous layer was extracted with toluene. The combined toluene layers were washed with 1N NaOH, treated with activated charcoal, and filtered through filter aid. The toluene was evaporated in vacuo and the residue crystallized from a 1:1 mixture of isopropyl acetate and hexanes to afford 5 grams of an off-white solid; 54% yield.. LRMS: 336.1 (M+1).
Method B Methyl-((3R.4R)-4.methvI-piperidin-'3-yl)-(7H-Pyrrolor2.3-dlpyrirnidin-4-vn.arnine To the product from Method A (0.7 grams, 2.19 mmol) dissolved in 15 mL of ethanol was added 1.5 mL of 2 N hydrochloric acid and the reaction mixture degassed by nitrogen purge. To the reaction mixture was then added 0.5 grams of 20% palladium hydroxide on carbon (50% water) (Aldrich) and the resulting mixture shaken (Parr-Shaker) under a 50 psi atmosphere of hydrogen at room temperature for 2 days. The Celite filtered reaction mixture was concentrated to dryness in vacuo and the residue purified by flash chromatography (silica; 5% methanol in dichoromethane) affording 0.48 grams (90%) of the title compound. LRMS: 246.1 (M+1). Method C
3->f(3R, 4R)-4^Methyl-3-rmethyl-(7H-pyrrolof2,3^dlPyrimidin^-vI)-amino1- piρeridin-1-yl -3-oχo-ρropionitrile
To a stirred solution of the product from Method B (1.0 g) dissolved in 30 L of ethanol was added 0.82 g of cyano-acetic acid 2,5^dioxo-pyrrolidin-1 -yl ester and the resulting mixture stirred at room temperature for 2 h. The reaction mixture was filtered through Celite® and concentrated in vacuo. The residue was redissolved in dichloromethane, washed with saturated, aqueous sodium bicarbonate, dried over sodium sulfate, filtered and concentrated to dryness in vacuo affording 1.1 g (86%) of the title compound as a yellow foam. LRMS: 313 (M + 1 ).
Example 7 1-f(3R, 4R)-4-Methyl-3-rmethvI-(7H'Pyrrolor2,3-dlpyrim»din-4.yl)-amino1- piperidin-1 -yl -ethaπone
To a stirred solution of the product from Method B (0.0$ grams, 0.114 mmol) dissolved in 5 mL of 10:1 dichloromethane/pyridine was added (0.018 grams, 0.228 mmol) of acetylchloride and the resulting mixture stirred at room temperature for 18 hours. The reaction mixture was then partitioned between dichloromethane and saturated sodium bicarbonate (NaHC03). The organic layer was washed again with saturated NaHC03, dried over sodium sulfate and concentrated to dryness in vacuo. The residue was purified by preparative thin layer chromatography (PTLC) (silica; 4% methanol in dichloromethane) affording 0.005 g (15%) of the title compound as a colorless oil.
The title compounds for examples 8-31 were prepared by a method analogous to that described in Example 7. Example 8
(3R,4R)-ri-(2-Amino-ethanesuIfonv0-4-methyl-piperidiπ-3"vπ-methyl-(7H- pyrrolof2.,3 d1pyrirrHdin-4-yl)-amιne
Example 9 3R,4R)-d-Ethanesulfonyl-4-methyl-piperidin-3-vπ-methyl-(7H'pyrrolof2,3- dlρyrimidin-4»v0-amine
Example 10 (3R,4R)-ri-(Butane-1-sulfonyl)-4'methyl-piperidin-3-vn"rnethγl-(7H-pyrrolQr2r3- d7pyrimidin- -y»-am e Example 11 (3R.4R)-4-Methyl-3-(rnethyl-(7H-pyrrplof2,3'd1PVrimid<n-4-yl)--arnino1' piperidiπe-1 -carboxylic acid isobutyl ester
Example 12
N-(2- (3R.4R)-4-Metrιyl-3-rmethyI-(7H^pyrrolof2,3-d1pyfimidin.4-yl -amiπo1- piperidiπe-1-sulfoπyl}*ethyl)-propionarnide
Example 13
(2-f(3R,4R>-4.Methyl-3-rmethyl-(7H-pyrrolor2.3-d1pyrimidin-4-vn-amino1- piperidine-1-sulfonylVethvD-carbamic acid methyl ester
Example 14 N-(2-f(3R<4R)- -Methyl-3-fmethyl-(7H-pyrroloF2,3-dlpyrimidin-4.yl)-amino1- ριperidine-1»sulfonγl)-ethylHsobutγrarnι"de
Example 15
(3R,4R)-(1-Methanesulfonyl-piperidin-3-yl)-methyl-(7H-Pyrrolof2,3-dlpyrimidiπ-
4-vQ-amine Example 16
((3R,4R)-1-Ethanesulfonyl-piperidin-3-vn-methyl-L7H-pyrrolof2.3-dlpyrimidin-
4-vI)'amine
Example 17 (3R.4R)-MethvM1-(propane-1-sulforιyl^Piperidiπ"3-vπ-(7H-pyrrolor2,3- dlpyrimidfπ-4-yl)-amine Example 18 (3R,4R)-ri-(Butane-1-sulfonvU-Piperidin-3-vn-methyl-(7H-Pyrrolor2,3- dlρyr»midin-4-yl)"amine
Example 19
2.2-DimethvI^N-((3R.4R)-2^4-methyl-3-rmethyl-(7H-pyrroIor2,3-dlPyrimidin^- yl)-amino1-piperidine-1-sulfonyl}-ethvD-propionarrtide Example 20
(3«f(3R.4R)-4-Methyl-3-rmethyl-(7H-pyrrolor2,3-dlpyrimidin-4-yl)-amiιiol- piperidin-1-yl}-3-oxo-propyl)-carbarnic acid tert-butyl ester
Example 21 MethvK(3R.4R)-4-methyl-1-(proρane-1-sulfonvn-pϊpi3ridin-3-vπ-(7H» ρyrrolof2.3-dlρyrimidiπ-4-yl)-amine
Example 22
3-Amino-1-f(3R.4R)-4«methyl-3-rmethvI-(7H-Pyrrolor2,3-dlpyrimidin^4-yl)- amiπo1»piperidϊn-1-γlVρropan-1-one
Example 23 2-Methoχv-1.f(3R,4R)-4-methyl-3-rmethyl-(7H-pyrrolor2<3»d1pyrimidin-4-yl - aminol-pϊperidin-1 -ylVethanoπe
Example 24 -Dimethylamiπo-1-^(3R,4R)-4-methyl-3-rmethyl-(7H-pyrrolof2,3-dlpyrimidin.4- yl)-amiπo1-pϊperid»n-1-yl «ethanone Example 25
(3-((3R,4R)-4-Methyl-3-fmethyl-(7H-pγrrolor2,3-d1pyrimidin-d-yl)-amino1. piperidin-1-yl)-3-oxo-propyl)-carhamic acid tert-butyl ester
Example 26 3.3.3-Trifluoro-1- (3R.4R}-4-methyl-3-rmethyl-(7H-ρyrrolor2.3-d1pyrimidin.4-vn. amino1-ρiperidin-1-ylVρropan-1-one Example 27 N-(2^(3R,4R)-4-MethVl-3-rmethyl-(7H-pyrrolor2.3-d1pyrimidin-4-vn-amiπo - ρiρeridin-1"yl>-2-oxo-ethyl)-acetamidfe Example 23 3-Ethoxy-1- (3R,4R)-4-methvI-3"rmethyl-(7H-Pyrrolof2,3^d1pyrimidin~4- yl>-aminol-ρiperidiπ-1^γl -propan-1-one Example 29 (3R,4R)-4-Methyl-3-fmethyl'(7H-pyrrolor2.3-dlpγrirπidin-4-yl)-aminoV piperidiπe-1 -carboxylic acid methylamide Example 30
(3R,4RM-Methyl-3 methvM7H-pγrroloT2.3-dlpyrimidin-4-vO'amino'l- piperidine-l-carboxylic acid diethylamide Example 31 (3R,4R)-Methyl-'f4'm6thvM-(2-methylamino-ethanesulfonyl)-piperidin" 3»ylH7H-pyrrolof2,3"d]pyrirrjidin-4-yl)-arnine

Claims

Claims 1. A method for resolving enantiomers of a compound containing the structure of the formula:
Figure imgf000040_0001
pharmaceutically acceptable acid addition salts thereof, pharmaceutically acceptable base addition salts thereof and free base thereof ; wherein y is 0, 1 or 2;
R4 is selected from the group consisting of hydrogen, (CrC6)alkyl, (Cr C6)alkylsulfonyl, (C2-Cβ)alkenyl, (C2-C6)alkynyl wherein the alkyl, alkenyl and alkynyl groups are optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C C4)aIkoxy, (C,-Ce)acyloxy, (Cι-CB)alkylamino, ((CrCeJal y a'amino, cyano, nitro, (C2-C6)alkenyl, (C2-C6)alkynyl or (C C6)acylamino; or R4 is (C3-Cι0)cycloalkyl wherein the cycloalkyl group is optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C C6)acyloxy, (C1-CB)acylamino, (C C5)alkylamino, ((c C6)alkyl)2amino, cyano,
Figure imgf000040_0002
trifluoromethyl(Cι-C6)alkyl, nitro, nitro(C1-Ce)alkyl or (CrCβ)acylamino;
R5 is (Cz-Cgjheterocycloalkyl wherein the heterocycloalkyl groups must be substituted by one to five carboxy, cyano, amino, deuterium, hydroxy, (C Cs)alkyl, (C CeJalkoxy, halo, (CτC6)acyl, (C Cδ)alkylamino, amino(C C6)a(kyl, (C C6)alkoxy-CO-NH, (C Ce)aIkylamino-CO-, (C2-CB)alkenyl, (C2-Ce) alkynyl, (Cr CB)alkylamino, aminofd-CeJalkyl, hydroxy(CrC6)alkyl, (Cj-CeJalkoxyfd-CeJalkyl, (C1-CB)acyloχy(C Ce)alkyl, nitro, cyanoζd- alkyl, haloζCrCβJal yl, nitro(C Cs)alkyl, trifluoromethyl, trifluoromethyl(C Ce)alkyl, (C C≤)acy)amino, (C,- Ce)acylamiπo(C C6)alkyl, (CrC6)aIkoxy(Ci-Ce)acylamino, amino(Cι-Ce)acyl, amino(C1-C5)acy|(C1-C6)alkyl, (CrC6)al ylamino(C 6)acyl, ((C
C6)alkyl)zamino(C C6)acyl, R1SR16N-CO-0-, R15R16N-CO-(C1-C6)alkyl, (CrC_)alkyl- S(0)m, Rl5R16NS(0)m, R^R^NS^^ td-CeJalkyl, R15S(0)rt R16N, Rl5S(0)mR1βN(Cr Ce)alkyl wherein m is 0, 1 or 2 and R 5 and R16 are each independently selected from hydrogen or (C Ce)alkyl; or a group of the formula
Figure imgf000041_0001
II wherein a is 0, 1 , 2, 3 or 4; b, c, e, f and g are each independently 0 or 1; d is O, 1, 2, or 3; X is S(0)„ wherein n is 0, 1 or 2; oxygen, carbonyl or -G(=N-cyano)-;
Y is S(0)p wherein n is 0, 1 or 2; or carbonyl; and
Z is carbonyl, C(0)0-, C(0)NR- or S(0)π wherein n is 0, 1 or 2;
Re, R7, R$, R9, R10 and R11 are each independently selected from the group consisting of hydrogen or (C C6)alkyl optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, {C Cs)acy\oxy, (CrC6)acylamino, (C C6)alkylamino, ((C
Ce)alkyl)2amino, cyano, cyaπo(C Ce)alkyl, trifluoromethyl(CrC6)alkyl, nitro, nitro(C1-C6)alkyl or (C Ce)acylamino;
R1Z is carboxy, cyano, amino, oxo, deuterium, hydroxy, trifluoromethyl, (C4-Cβ)alkyl, trif!uorσmethyl(CπCβ)alkyl, (C C6)alkoxy, halo, (Cι-Ce)acyl, (CrCe)alkylamino, ((C C6)alkyl)z amino, amino(C C6)alkyl, (CrC6)alkoxy-CO-NH, (C CeJalkyla ino-CO-,
(C2-C3)alkenyl, (C2-C6) alkynyl, (CrCs)alkylamino, hydroxy(CrCe)aIkyl, (C
C6)alkoxy(CrCβ)alkyl, (Cι-C6)acyloxy(Cι-Cβ)alkyl, nitro, cyano(CrCβ)alky), halo(C,-
Cβ)alkyl, nitro(C C6)alkyl, trifluoromethyl, trifIuoromethyI(CrCe)alkyl, (C
C6)acylamϊno, (d-CeJacylaminofC CeJalkyl, (C1-CB)alkoxy(CrC6)acylamino7 amino(CrC6)acyi, amiπo(C CB)acyl(C1-C6)alkyl, (CrC6)alkylamino(CrCe)acyl, ((Cr
Ce)alkyl)2amiπo(CrC6)acyl, R15R 6N-C0-0-, R15R1βN-C0-(Cl-C6)alkyl, RlSC(0)NH,
RnSOC(0)NH, R15NHC(0)NH, (CrC6)alkyl-S(0)m,
Figure imgf000041_0002
R15Rl6NS(0)m, R15R1$NS(0)m (CrC6)alkyl, R sS(0)m R BN, R15$(0)mR16N(C C6)alkyl wherein m is 0, 1 or 2 and R15 and R 6 are each independently selected from hydrogen or (d-CβJalkyl; said method comprising the steps of: a) mixing a racemic mixture of enantiomers of a compound, containing the structure of said formula; in a solvent, with a resolving compound having a defiπed stereospecificity, to form a solution and with said resolving agent being capable of binding with at least one but not all of said enantiomers to form a precipitate, containing said at least one of said enantiomers, b) allowing the mixture to stand for a time sufficient to allow substantial precipitation of a stereospecific enantiomer of the racemic mixture from the solution and wherein another of said enantiomers remains in said solution; and c) depending on the stereospecific enantiomer of the compound which is desired, collecting either the precipitate and purifying it or collecting the solution with contained other of said enantiomers and recrystallizing the enantiomer contained in said solution,
2. The method of claim 1 , wherein said resolving compound is selected from tartaric acid and its derivatives and adeno acid and derivatives thereof.
3, The method of claim 2, wherein said tartaric acid derivatives comprise toluoyl and benzoyl tartaric acids in stereospecific conformation. 4. The method of claim 3, wherein the tartaric acid derivative is di-p- toluoyl-L-tartaric acid.
5. The method of claim 2, wherein the adeno acid comprises (-) phencyphos.
6. The method of claim 1 , wherein the compound is
Figure imgf000042_0001
7. The method of claim 1, wherein the compound is converted to an acid addition salt form thereof prior to said resolution step.
8. The method of claim 7, wherein said addition salt form is a hydrochloride salt form.
9. The method of claim 1, wherein the temperature at which the resolution and precipitation is effected is ambient temperature and the time is no more than about four hours.
10. The method of claim 7, wherein the hydrochloride salt of the compound is formed in a solvent selected from the group consisting of methanol, ethanol, isopropanol, acetonitrile, tetrahydrofuran, water, toluene, ethylacetate, dichloromethane, dichloroethane, and mixtures thereof. 11. The method of claim 9, wherein said solvent in which the hydrochloride salt is formed comprises ethanol with a minor amount of toluene as cosolvent.
12. The method of claim 1 , wherein the solvent is selected from the group consisting of ethyl acetate, toluene, acetonitrile, heptane, water and mixtures thereof. 13. The method of claim 1, wherein seeds crystals of the precipitating enantiomer are added to facilitate said precipitation.
14. A method for preparing the compound of the formula
Figure imgf000043_0001
or the pharmaceutically acceptable salt thereof; wherein R1 is a group of the formula
Figure imgf000043_0002
wherein y is 0, 1 or 2;
R4 is selected from the group consisting of hydrogen, (C Cβ)alkyl, (C Cs)alkylsulfonyl, (C2-C6)alkeπyl, (C2-Cβ)alkynyl wherein the alkyl, alkenyl and alkynyl groups are optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (Cr C4)alkoxy, (d-C6)acyloxy, (d-C6)aIkylamino, ((d-C6)aIkyl)2amino, cyano, nitro, (C2-C6)alkenyl, (CrC6)alkynyl or (C C6)acylamino; or R4 is (C3-C10)cycloalkyl wherein the cycloalkyl group is optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C C6)acyloχy, (d-Ce)acylamino, (d-Cs)alkylamino, ((Ci- C6)alkyl)2amino, cyano, cyano(C,-C6)alkyl, trifluoromethyl(C1-C6)alkyl, nitro, nitro(C.,-C6)alkyl or (C-,-C6)acylanniπα; R5 is (C C9)heterocycloalkyl wherein the heterocycloalkyl groups must be substituted by one to five carboxy, cyano, amino, deuterium, hydroxy, (d-CβJalkyl, (d-Ce)alkoxy, halo, (d-C6)acyl, (d-Ca)alkylamino, amino(CrCe)alkyl, (C Ce)alkoxy-CO-NH, (C C6)alkylamino-CO-, (Ca-C6)alkenyl, (C Ce) alkynyl, (C,- 5 C6)alkylamino, amino(C1-C6)alkyl, hydroxy(C1-C6)alkyl, (CrC6)alkoxy(Cι-C6)alkyl, (Cι-C6)acyloxy(C C6)aIkyl, nitro, cyano(d-C6)alkyl, halo(d-C6)alkyl, nitro(C C6)alkyl, trifluoromethyl, trifluoromethyl(CrC6)alkyl, (C C6)acylamino, (d- C6)acylamino(C1-C6)alkyl, (C1-C3)alkoxy(C Ce)acylamino, amino(CrCa)acyl, amino(C1-C6)acyl(C1-C3)alkyl,
Figure imgf000044_0001
((d-
10. C6)alkyl)2amino(C1-C6)acyl, R15RιeN-CO-0-, R15R 6N-CO-(C C6)alkyl, (CrC6)alkyl- S(0)m, R,sR,eNS(0)m, R15R16NS(0)m(d-C6)alkyl, R^SfO) , R16N, R1sS(0)mR16N(C C6)alkyl wherein m is 0, 1 or 2 and R15 and R β are each independently selected from hydrogen or (d-Ce)alkyl; or a group of the formula II
Figure imgf000044_0002
II
15 wherein a is 0, 1 , 2, 3 or 4; b, c, e, f and g are each independently 0 or 1 ; d is 0, 1 , 2, or 3;
X is S(0)n wherein n is 0, 1 or 2; oxygen, carbonyl or -C(=N-cyano)-; Y is S(0)n wherein n is 0, 1 or 2; or carbonyl; and 0 Z is carbonyl, C(0)0-, C(0)NR- or S(0)π wherein n is 0, 1 or 2;
R6, R7, R8, R9, R10 and R11 are each independently selected from the group consisting of hydrogen or (C Ce)alkyl optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C Cβ)acyloxy, (C Cβ)acylarnino, (C-pC6)alkylamino, ((Cr
C6)alkyl)2amino, cyano, cyano(C1-CB)alkyl, trifluoromethyl(C1-Ce)alkyl, nitro, 5 nitrα(C,-Ce)alkyl or (CrCs)acylamino;
R 2 is carboxy, cyano, amino, oxo, deuterium, hydroxy, trifluoromethyl, (d-C6)alkyl, trifluoromethy d-CeJalkyl, (C C6)alkoxy, halo, (C CB)acyl,
Figure imgf000044_0003
((d- C6)alkyl)2 amino, amiπo(d-CB)alkyl, (CrC6)alkoxy-CO-NH, (C CeJalkylamino-CO-, (C2-Cβ)alkenyl, (C2-CB) alkynyl, (C C6)alkylamino, hydroxy(C1-C6)alkyl, (C CB)alkoxy(CrC6)alkyl, (Cι-C6)acyloxy(CrC6)alkyl, nitro, cyano(C CB)alkyl, halo(d- C6)alkyl, nitro(CrC6)alkyl, trifluoromethyl, trifluoromethyl(C C6)alkyl, (d- C6)acylamino, (d-C6)acylamino(d-Ce)alkyl, (Cι-C6)alkoxy(Cι-CB)acylamino,
Figure imgf000045_0001
amiπo(CrC6)acyl(Cι-C6)alkyl, (d-CsJalkylaminoCCrCsJacyl, ((C C6)alkyl)2amino(C1-C6)acyl, R 5R16N-CO-0-, R 5R16N-CO-(C C6)alkyl, R15C(0)NH, R1S0C(0)NH, R15NHC(0)NH, (d-C6)alkyl-S(0)m, (CrC6)alkyl-S(0)m-(CrC6)alkyl, R15R16NS(0)m, R15RιeNS(0)m (C C$)alkyl, Rl5S(0)m R16N, R 5S(0)mR 6N(CrC6)alkyl wherein m is 0, 1 or 2 and RlS and R1$ are each independently selected from hydrogen or (C Ce)alkyl;
R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, amino, halo, hydoxy, nitro, carboxy, (C2-Ce)alkenyl, (C2- C6)alkynyl, trifluoromethyl, trifluoromethoxy, (C C6)alkyl, (C C6)alkoxy, (C3- C10)cycloalkyl wherein the alkyl, alkoxy or cycloalkyl groups are optionally substittued by one to three groups selected from halo, hydroxy, carboxy, amino (C Cβ)alkylthio, (C Ce)alkylamiπo, ((d-C6)alkyl)2amino, (C5-C9)heteroaryl, (C C9)heterocycloalkyl, (C3-C9)cycloalkyI or (d-C^ary!; or R2 and R3 are each independently (C3- C10)cycloalkyl, (C3-C10)cycloalkoxy, (Cι-Ce)alkylamino, ((C C6)al yl)2ami o, (C6- Cιo)arylamino, (d-C6)alkylthio, (C5-C10)arylthio, (d-Cβ)alkylsulfinyl, (C6- Cιo)arylsulfinyl, (CrCe)alkylsulfonyl, (C6-C 0)arylsulfonyl, (CrC6)acyl, (Cι-Cβ)alkoxy- CO-NH-, (Ci-CeJalkyamino-CO-, (Cs-C9)heteroaryl, (C C9)heterocycloalkyl or (C6- Cιo)aryl wherein the heteroaryl, heterocycloalkyl and aryl groups are optionally substituted by one to three halo, (C C6)alkyl, (CrC6)alkyI-CO-NH-, (C C6)alkoxy- CO-NH-, (CrCB)alkyl-CO-NH-(CrCB)alkyl, (C C6)alkoxy-CO-NH-(C C_)alkyl, (d- C6)alkoxy-CO-NH-(C1-C6)alkoxy, carboxy, carboxy(d-C6)alkyl. carboxy(C CB)alkoxy, benzyloxycarbonyl(d-C6)alkoxy, (d-C3)alkoxycarboπyl(Cι-C6)a!koxy, (Cβ-C10)aryl, amino, amino(C C6)alkyl, (C-,-C6)aIkoxycarbonylamino, (C6-C10)aryl(Cι- C6)alkoxycarbonylamino, (d-CsJalkylamϊnσ, ((C CB)alkyl)2amino, (C,- C6)alkylamiπo(d-C$)alkyl, ((d-Cβ)alkyl)2amino(CrC6)alkyl, hydroxy, (d-C6)alkoxy, carboxy, carboxy(Cι-Ce)alkyl, (Cι-C6)alkoxycarbonyl, (C C6)alkoxycarbonyl(Cr Ce)alkyl, (CrC6)alkoxy-CO-NH-, (CrC6)alky]-CO-NH-, cyano, (Cs-C^heterocycloalkyl, amino-CO-NH-, (d-C6)alkylamino-CO-NH-, ((C C6)alkyl)2amino-CO-NH-, (Ce- C10)arylamino-CO-NH-, (C5-C9)heteroarylamino-CO-NH-, (C Cs)alkylamino-CO-NH- (C C6)alkyl, ((C-CeJalky zamino-CO-NH CrCgJalkyl, (C6-C10)arylamino-CO-NH-(Cr C6)alkyl, (C5-C9)heteroarylamino-CO-NH-(CrC6)alkyl, (Cι-Cβ)alkylsulfonyl, (d- C6)alkylsulfonylamino, (C1-Ce)alkylsulfonylamino(CrC6)alkyl) (C6-C10)arylsulfonyl, (Ca- C10)arylsulfonylamino, (Cβ-C1o)arylsulfόnylamino(CrC6)alkyl, (C,~
C6)alkylsulfoπylamino, (C C6)alkyIsulfonylamiπo(C C6)alkyl, (C3-C9)heteroaryl or (d- C9)heterαcycloalkyl; said method comprising the steps of: b) mixing a racemic mixture of enantiomeric compounds of the formula
Figure imgf000046_0001
wherein y, R4 and R5 are as defined above, in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with said resolving agent being capable of binding with at least one but not all of said enantiomers to form a precipitate, containing said at least one of said enantiomers, b) allowing the mixture to stand for a time sufficient to allow substantial precipitation of a stereospecific enantiomer of the racemic mixture from the solution and wherein another of said enantiomers remains in said solution; c) depending on the stereospecific enantiomer of the compound which is desired, collecting either the precipitate and purifying it or collecting the solution with contained other of said enantiomers and recrystallizing the enantiomer contained in said solution; and d) reacting the desired stereospecific enantiomer so formed with a compound of the formula
Figure imgf000046_0002
wherein R is hydrogen or a protecting group and R2 and Rs are as defined above. 15. A compound of the formula
Figure imgf000047_0001
wherein Rz and R3 are each independently selected from the group consisting of hydrogen, deuterium, amino, halo, hydoxy, nitro, carboxy, (C2- C6)alkenyl, (C2-C6)alkynyl, trifluoromethyl, trifluoromethoxy, (d-C6)alkyl, (d- C6)alkoxy, (C3-Cιo)cycloalkyl wherein the alkyl, alkoxy or cycloalkyl groups are optionally substittued by one to three groups selected from halo, hydroxy, carboxy, amino (d-CB)alkylthio, (d-CB)alkylamino, ((d-C6)al yl)2a ino, (C5-C9)heteroaryl, (C2-C9)heterocyc(oalkyl, (C3-C9)cycloalkyl or (C6-C1p)aryl; or R2 and R3 are each independently (C3-C10)cycloalkyl, (C3-C10)cycloalkoxy, (Cι-C6)alkylamino, ((C C6)alkyl)2amiπo, (Ce-C1ή)arylamino, (d-CB)alkylthio, (Cβ-Cl0)arylthio, (C C6)alkylsulfinyl, (C6-C10)arylsulfinyl, (C Ce)alkylsulfonyl, (C6-C10)arylsulfonyl7 (d- C6)acyl, (d-Cβ)alkoxy-CO-NH-, (d-d)alkyamino-CO-, (C5-Cg)heteroaryl, (C2- C9)heterocycloalkyl or (Ce-do)aryl wherein the heteroaryl, heterocycloalkyl and aryl groups are optionally substituted by one to three halo, (C Cβ)alkyl, (CrCB)alkyl-CO- NH-, (d-Ce)alkoxy-CO-NH-, (C C6)alkyl-CO-NH-(d-C6)alkyl, (d-CB)alkoxy-CO- NH-(C C6)alkyl, (d-C6)alkoxy-CO-NH-(d-C6)alkoxy, carboxy, carboxy(d-C6)alkyl, carboxy(C1-C6)alkoxy, benzylαxycarbonyl(C1-C6)alkoxy, (d-Cβ)alkoxycarbonyl(d- C6)alkoxy, (C6-C10)aryl, amino, amino(Cι-C6)alkyl, (Cι-C6)alkoxycarbonylamino, (C3- C1Q)aryl(CrC6)alkoxycarbonylamino, (CrC6)alkylamino, ((C C6)alkyl)2amino, (d- C6)alkylamino(CrC6)alkyl, (( -CeJalky aamino -Ce alkyl, hydroxy, (C Ce)alkoxy, carboxy, carboxy(CrC6)alkyl, (CrC6)alkoxycarbonyl, (Cl-C6)alkoxycarbonyl(C1- Cβ)alkyl, (C CB)alkoxy-CO-NH-, (C CB)alkyl-CO-NH-, cyano, (C5- C9)heterocycloalkyl, amino-CO-NH-, (C C6)alkylamino-CO-NH-, ((d- C6)alkyl)2amino-CO-NH-, (CB-dD)arylamino-CO-NH-, (C3-C9)heteroarylamino-CO- NH-, (C CB)alkylamino-CO-NH-(CrC6)alkyl, ((CrC6)alkyl)2arnino-CO-NH-(d- C6)alkyl, (C6-do)arylamino-CO-NH-(CrCB)alkyl, (C5-Cg)heteroarylamino-CO-NH- (CrC6)alkyl, (d-C6)alkylsulfonyl, (d-C6)alkylsulfonylamino, (C
C6)alkylsulfonylamino(d-C6)alkyl, (C6-C1D)arylsulfonyl, (C6-C10)arylsulfonylamino, (C6-C10)arylsulfonylamino(C1-Ce)alkyl, (CrCB)alkylsulfonylamino, (d-
C6)alkylsulfonylamino(Cι-C6)alkyl, (C3-C9)heteroaryl or (C2-C9)heterocycIoalkyl.
16. A compound according to claim 15, wherein R2 and R3 are hydrogen.
17. A compound selected from the group consisting of: Methyl-[(3R,4R)-4-methyl-1-(propane-1-sulfonyl)-piperidin-3-yl]-(7H- pyrrαlo[2,3-d]pyrimidin-4-y!)-amine;
(3R,4R)-)-4-Methyl-3-[methyi-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]- piperidine-1 -carboxylic acid methyl ester;
3,3,3-Trifluoro-1-{(3R,4RH-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)-amino]-piperidin-1-yl}-propan-1-one;
(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]- piperidiπe-1 -carboxylic acid dimethylamide;
{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]- ρiperidine-1 -carbonyl}-amino)-acetic acid ethyl ester; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]- piperidin-1-yl}-3-oxo-propionitrile;
3,3,3-Trifluoro-1-{(3R,4R)-4-methyl-3-[methyl-(5-methyl-7H-ρyrroloi;2,3- d]pyrimidin-4-yl)-amino]-piperidiπ-1 -yl}-proρan-1 -one;
1-{(3R,4R)-4- ethyl-3-(methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]- piperidin-1-yl}-but-3-yn-1 -one;
1-{(3R,4R)-3-[(5-Chloro-7H-pyrrolo[2,3-d]pyrimidiπ-4-yl)-methyl-amino]^- methyl-piperidin-1 -yi}-propaπ-1 -one;
H(3R,4R)-3-[(5-Fluoro-7H-pyrroIo[2,3-d]pyrimidin-4-yl)-methyl-amino]-4- methyl-piperidiπ-1-yl}-proρan-1-one; (3R,4R)-N-cyano-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidϊπ-4-yl)-amino]-
N'-propyl-piperidine-l-carboxamidine; and
(3R,4R)-N-cyano-4,N,,N'-Trimethyl-3-[methyl-(7H-ρyrrolo[2,3-d]pyrimidin-4-yl)- amino]-piperidine-1-carboxamidine.
1$. A pharmaceutical composition for (a) treating or preventing a disorder or condition selected from organ transplant rejection, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia and other autoimmune diseases or (b) the inhibition of protein kinases or Janus Kinase 3 (JAK3) in a mammal, including a human, comprising an amount of a compound of claim 16 or a pharmaceutically acceptable salt thereof, effective in such disorders or conditions and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition for (a) treating or preventing a disorder or condition selected from organ transplant rejection, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia and other autoimmune diseases or (b) the inhibition of protein kinases or Janus Kinase 3 (JAK3) in a mammal, including a human, comprising an amount of a compound of claim 16 or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional agents which modulate a mammalian immune system or with aπtiiπflammatory agents, effective in such disorders or conditions and a
•r pharmaceutically acceptable carrier. 20. A method for the inhibition of protein kinases or Janus Kinase 3
(JAK3) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of claim 16 or a pharmaceutically acceptable salt thereof.
21. A method for treating or preventing a disorder or condition selected from organ transplant rejection, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia and other autoimmune diseases in a mammal, including a human, comprising administering to said mammal an amount of a compound of claim 16 or a pharmaceutically acceptable salt thereof, effective in treating such a condition.
22. A method for the inhibition of protein kinases or Janus Kinase 3 (JAK3) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of claim 16 or a pharmaceutically acceptable salt thereof alone or in combination with one or more additional agents which modulate a mammalian immune system or with antiinflammatory agents.
23. A method for treating or preventing a disorder or condition selected from organ transplant rejection, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia and other autoimmune diseases in a mammal, including a human, comprising administering to said mammal an amount of a compound of claim 16 or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional agents which modulate a mammalian immune system or with antiinflammatory agents, effective in treating such a condition.
24. A compound of the formula
Figure imgf000050_0001
25. A compound of the formula
Figure imgf000050_0002
26. A compound of the formula
Figure imgf000050_0003
PCT/IB2002/001905 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors WO2002096909A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
JP2003500088A JP4381137B2 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and its use for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinase inhibitors
SK50033-2011A SK288192B6 (en) 2001-05-31 2002-05-29 3-((3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- amino]-piperidinyl)-3-oxo-propionitrile and pharmaceutical composition comprising it
AU2002304401A AU2002304401C1 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
IL15858802A IL158588A0 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) - methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinase inhibitors
PL409305A PL228155B1 (en) 2001-05-31 2002-05-29 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile and the pharmaceutical composition and their use
KR10-2003-7015681A KR20040003037A (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
SK1465-2003A SK288199B6 (en) 2001-05-31 2002-05-29 Method for resolving enantiomers of (1-benzyl-4-methylpiperidin- 3-yl)-methylamine
MXPA03011062A MXPA03011062A (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors.
NZ530380A NZ530380A (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
KR1020087018519A KR100926875B1 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
EA200301193A EA007251B1 (en) 2001-05-31 2002-05-29 3-{(3R, 4R) -4-METHYL-3-(7H-PYRROLO[2,3-d] PYRIMIDINE-4-YL)AMINO]PIPERIDIN-1-YL}-3-OXO-PROPIONITRILE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
CA002448281A CA2448281C (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
BR0209246-8A BR0209246A (en) 2001-05-31 2002-05-29 Chiral Salt Resolution
EEP200300594A EE05332B1 (en) 2001-05-31 2002-05-29 3 - {(3R, 4R) -4-Methyl-3- [methyl (7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino] piperidine- 1-1} -3-oxopropionitrile, a pharmaceutically acceptable salt thereof, and uses thereof
UA20031110841A UA80093C2 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
HU0400152A HU230876B1 (en) 2001-05-31 2002-05-29 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile as protein kinase inhibitor
EP02733058A EP1392694A1 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors
IS6993A IS3023B (en) 2001-05-31 2003-10-13 3 - ((3R, 4R) -4-methyl-3- [methyl- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -amino] -piperidinyl) -3-oxo-propionitrile as a protein kinase inhibitor
HR20030943A HRP20030943B1 (en) 2001-05-31 2003-11-19 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
NO20035201A NO328578B1 (en) 2001-05-31 2003-11-24 Compound and its use, and pharmaceutical composition
BG108389A BG66489B1 (en) 2001-05-31 2003-11-27 3-((3R,4R)-4-METHYL-3-[METHYL-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-AMINO]-PIPERIDIINYL)-3-OXO-PROPIONITRILE AS PROTEIN KINASE INHIBITOR
AU2008203170A AU2008203170B2 (en) 2001-05-31 2008-07-16 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
NO20093135A NO20093135L (en) 2001-05-31 2009-10-13 Optical solution of (1-benzyl-4-methylpiperidin-3-yl) methylamine and its use in the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinase inhibitors
NO2017047C NO2017047I1 (en) 2001-05-31 2017-09-08 Tofacitinib, optionally in the form of a pharmaceutically acceptable salt, including citrate salt

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US60/294,775 2001-05-31
US34104801P 2001-12-06 2001-12-06
US60/341,048 2001-12-06

Publications (1)

Publication Number Publication Date
WO2002096909A1 true WO2002096909A1 (en) 2002-12-05

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/001905 WO2002096909A1 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors

Country Status (52)

Country Link
US (2) US7301023B2 (en)
EP (3) EP1392694A1 (en)
JP (1) JP4381137B2 (en)
KR (5) KR100869409B1 (en)
CN (1) CN1729192A (en)
AP (1) AP1859A (en)
AR (2) AR037321A1 (en)
AT (1) ATE519741T1 (en)
AU (2) AU2002304401C1 (en)
BE (1) BE2017C032I2 (en)
BG (1) BG66489B1 (en)
BR (1) BR0209246A (en)
CA (1) CA2448281C (en)
CL (1) CL2008000762A1 (en)
CR (1) CR10177A (en)
CU (1) CU23337B7 (en)
CY (2) CY1113322T1 (en)
CZ (1) CZ304366B6 (en)
DK (1) DK1666481T3 (en)
EA (2) EA007251B1 (en)
EC (1) ECSP034865A (en)
EE (1) EE05332B1 (en)
ES (2) ES2393385T3 (en)
FR (1) FR17C1031I2 (en)
GE (1) GEP20063784B (en)
GT (2) GT200200100A (en)
HR (1) HRP20030943B1 (en)
HU (2) HU230876B1 (en)
IL (1) IL158588A0 (en)
IS (1) IS3023B (en)
LT (1) LTC1666481I2 (en)
LU (1) LUC00031I2 (en)
MA (1) MA27029A1 (en)
MX (1) MXPA03011062A (en)
MY (1) MY129649A (en)
NL (1) NL300887I2 (en)
NO (3) NO328578B1 (en)
NZ (2) NZ530380A (en)
OA (1) OA12612A (en)
PA (1) PA8546301A1 (en)
PE (1) PE20030561A1 (en)
PL (2) PL228155B1 (en)
PT (1) PT1666481E (en)
RS (1) RS52144B (en)
SI (1) SI1666481T1 (en)
SK (2) SK288192B6 (en)
TN (1) TNSN03128A1 (en)
TW (2) TWI316061B (en)
UA (1) UA80093C2 (en)
UY (1) UY27317A1 (en)
WO (1) WO2002096909A1 (en)
ZA (1) ZA200307982B (en)

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6965027B2 (en) 2001-12-06 2005-11-15 Pfizer Inc. Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7335667B2 (en) 2004-12-22 2008-02-26 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors
US7358250B2 (en) 2004-06-29 2008-04-15 Amgen Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7598257B2 (en) 2005-12-13 2009-10-06 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US7655797B2 (en) 2002-02-01 2010-02-02 Rigel Pharmaceuticals, Inc. Intermediates for making 2,4-pyrimidinediamine compounds
USRE41783E1 (en) 1999-12-10 2010-09-28 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine compounds
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7834022B2 (en) 2007-06-13 2010-11-16 Incyte Corporation Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US7879844B2 (en) 2005-12-28 2011-02-01 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2011045702A1 (en) 2009-10-15 2011-04-21 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
WO2011075334A1 (en) 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
WO2011097087A1 (en) 2010-02-05 2011-08-11 Pfizer Inc. Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US8232394B2 (en) 2005-07-29 2012-07-31 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2012135338A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Processes for preparing tofacitinib salts
WO2012137111A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
US8299084B2 (en) 2009-04-20 2012-10-30 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of Janus kinase 3
US8309566B2 (en) 2008-02-15 2012-11-13 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
WO2012152440A1 (en) 2011-05-11 2012-11-15 Ratiopharm Gmbh Composition for modified release comprising ranolazine
WO2013090490A1 (en) 2011-12-15 2013-06-20 Ratiopharm Gmbh Tofacitinib salts
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
US8563541B2 (en) 2005-09-22 2013-10-22 Incyte Corporation Azepine inhibitors of Janus kinases
WO2014016338A1 (en) 2012-07-25 2014-01-30 Lek Pharmaceuticals D.D. New synthetic route for the preparation of 3-amino-piperidine compounds
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2014128591A1 (en) 2013-02-22 2014-08-28 Pfizer Inc. Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
WO2014147526A1 (en) 2013-03-16 2014-09-25 Pfizer Inc. Tofacitinib oral sustained release dosage forms
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
EP2813228A1 (en) 2013-04-25 2014-12-17 Japan Tobacco Inc. Agent for improvement of skin barrier function
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8952027B2 (en) 2008-04-16 2015-02-10 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
WO2015083028A1 (en) 2013-12-05 2015-06-11 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9260438B2 (en) 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
EP3078665A1 (en) 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
WO2016178110A1 (en) 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9512161B2 (en) 2009-10-09 2016-12-06 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9593082B2 (en) 2005-06-08 2017-03-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9662332B2 (en) 2011-11-30 2017-05-30 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
WO2017125417A1 (en) 2016-01-18 2017-07-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Tofacitinib as vaccination immune modulator
WO2018004306A1 (en) 2016-06-30 2018-01-04 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
WO2018169373A1 (en) 2017-03-17 2018-09-20 Daewoong Pharmaceutical Co., Ltd. Pyrrolotriazine derivatives as kinase inhibitor
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10174036B2 (en) 2015-04-29 2019-01-08 Wuxi Fortune Pharmaceutical Co., Ltd Substituted pyrazoles as JAK inhibitors
US10174056B2 (en) 2015-05-29 2019-01-08 Wuxi Fortune Pharmaceutical Co., Ltd Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR20190064215A (en) 2017-11-30 2019-06-10 보령제약 주식회사 Pharmaceutical Composition Comprising Tofacitinib
WO2019132560A1 (en) 2017-12-28 2019-07-04 주식회사 대웅제약 Amino-fluoropiperidine derivative as kinase inhibitor
WO2019132562A1 (en) 2017-12-28 2019-07-04 주식회사 대웅제약 Oxy-fluoropiperidine derivative as kinase inhibitor
WO2019132561A1 (en) 2017-12-28 2019-07-04 주식회사 대웅제약 Amino-methyl piperidine derivative as kinase inhibitor
US20190231782A1 (en) * 2018-01-31 2019-08-01 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
EP3539965A1 (en) 2013-12-09 2019-09-18 Unichem Laboratories Limited An improved process for the preparation of (3r,4r)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10617690B2 (en) 2015-01-20 2020-04-14 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitor
KR102131107B1 (en) 2019-01-15 2020-07-07 주식회사 다산제약 Novel method for preparing 3-amino-piperidine
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
WO2020198583A1 (en) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Bicyclic jak inhibitors and uses thereof
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
WO2021094953A1 (en) 2019-11-14 2021-05-20 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
WO2021107590A1 (en) 2019-11-25 2021-06-03 주식회사 대웅제약 Novel triazolopyridine derivative and pharmaceutical composition comprising same
WO2021198980A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
WO2022194782A1 (en) * 2021-03-15 2022-09-22 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
EP3927689A4 (en) * 2019-04-05 2022-11-30 Yuhan Corporation Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
ATE323704T1 (en) * 2000-06-26 2006-05-15 Pfizer Prod Inc PYRROLO¬2,3-DÄPYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE ACTIVE INGREDIENTS
DE60322544D1 (en) * 2002-08-27 2008-09-11 Merck Patent Gmbh GLYCINAMIDE DERIVATIVES AS RAF KINASE INHIBITORS
CN1717236A (en) 2002-11-26 2006-01-04 辉瑞产品公司 Method of treatment of transplant rejection
JP2007536310A (en) * 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト Combination comprising S1P receptor agonist and JAK3 kinase inhibitor
TW200615268A (en) 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
JP2008520612A (en) * 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト Combination of JAK inhibitor and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitor
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
KR20110050654A (en) * 2008-08-01 2011-05-16 바이오크리스트 파마수티컬즈, 인코퍼레이티드 Piperidine derivatives as jak3 inhibitors
JP4884570B2 (en) 2008-08-20 2012-02-29 ファイザー・インク Pyrrolo [2,3-d] pyrimidine compound
CA2752150A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
CA2773182A1 (en) * 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibitors of jak
WO2011086053A1 (en) * 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
CN104955803B (en) * 2012-11-30 2017-11-28 斯洛文尼亚莱柯制药股份有限公司 3 aminopiperidines are prepared by nitro tetrahydropyridine precursor
WO2014097150A1 (en) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of tofacitinib and intermediates thereof
US9670160B2 (en) 2012-12-28 2017-06-06 Glenmark Pharmaceuticals Limited Process for the preparation of tofacitinib and intermediates thereof
CN104513248B (en) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 A kind of purification process of tropsch imatinib intermediate
US10479763B2 (en) 2015-02-17 2019-11-19 Amorepacific Corporation Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives
CN104761556B (en) * 2015-03-21 2017-06-23 河北国龙制药有限公司 Support method replaces cloth impurity and its synthetic method, and support method for the quality control method of cloth for cloth intermediate impurities, support method
KR101964546B1 (en) * 2015-07-27 2019-04-01 유니켐 레버러토리스 리미티드 Topicality nip oral disintegration tablet
KR101771219B1 (en) * 2015-08-21 2017-09-05 양지화학 주식회사 Janus kinase 1 selective inhibitors and their pharmaceutical use
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
CN105348287A (en) * 2015-11-30 2016-02-24 宁波立华制药有限公司 Novel synthesis process of tofacitinib citrate
KR102565407B1 (en) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 Method for chiral resolution of n-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives by using polar aprotic solvent
CN106831538B (en) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 The preparation method of tropsch imatinib intermediate
CN107602569A (en) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 A kind of new pyrrole simultaneously [2,3 d] pyrimidine compound and its preparation method and use
WO2020183295A1 (en) 2019-03-13 2020-09-17 Intas Pharmaceuticals Ltd. Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814477A (en) * 1984-10-24 1989-03-21 Oce-Nederland B.V. Dioxaphosphorinanes, their preparation and use for resolving optically active compounds
JPH07330732A (en) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd Optically active 3-amino-1-benzylpiperidine derivative
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO1999065908A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2001042246A2 (en) * 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2002000661A1 (en) * 2000-06-26 2002-01-03 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ES2109796T3 (en) 1994-05-03 1998-01-16 Ciba Geigy Ag DERIVATIVES OF PIRROLOPIRIMIDILO WITH ANTIPROLIFERANTE EFFECT.
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
DK0831829T3 (en) 1995-06-07 2003-12-15 Pfizer Heterocyclic, ring-condensed pyrimidine derivatives
US6066638A (en) 1995-07-05 2000-05-23 E. I. Du Pont De Nemours And Company Fungicidal pyrimidinones
TR199800012T1 (en) 1995-07-06 1998-04-21 Novartis Ag Pyrolopyrimidines and applications for preparation.
AR004010A1 (en) 1995-10-11 1998-09-30 Glaxo Group Ltd HETERO CYCLIC COMPOUNDS
EA000072B1 (en) 1995-11-14 1998-06-25 Фармация Энд Апджон С.П.А. Aryl and heteroaryl purine compounds
WO1997027199A1 (en) 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
CH690773A5 (en) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo (2,3-d) pyrimides and their use.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (en) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ID19430A (en) 1996-07-13 1998-07-09 Glaxo Group Ltd COMPOUND HETEROSICLIC COMPOUND
DE69738468T2 (en) 1996-08-23 2009-01-08 Novartis Ag SUBSTITUTED PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
KR20000057228A (en) 1996-11-27 2000-09-15 디. 제이. 우드, 스피겔 알렌 제이 Fused bicyclic pyrimidine derivatives
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
AU6568398A (en) * 1997-03-24 1998-10-20 Pharmacia & Upjohn Company Method for identifying inhibitors of jak2/cytokine receptor binding
WO1999051599A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
EP1082311A1 (en) 1998-05-28 2001-03-14 Parker Hughes Institute Quinazolines for treating brain tumor
EP1091739A1 (en) 1998-06-30 2001-04-18 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
HUP0103386A3 (en) 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
GT200200234A (en) 2001-12-06 2003-06-27 NEW CRYSTAL COMPOUNDS
WO2006004703A2 (en) * 2004-06-29 2006-01-12 Amgen Inc. PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814477A (en) * 1984-10-24 1989-03-21 Oce-Nederland B.V. Dioxaphosphorinanes, their preparation and use for resolving optically active compounds
JPH07330732A (en) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd Optically active 3-amino-1-benzylpiperidine derivative
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO1999065908A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2001042246A2 (en) * 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2002000661A1 (en) * 2000-06-26 2002-01-03 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAYLEY C. R. ET AL.: "Resolution of Racemates by Diastereomeric Salt Formation", 1992, J. WILEY & SONS, ENGLAND, XP002208814 *
JACQUES, JEAN: "Enantiomers, racemates, and resolutions", 1981, J. WILEY & SONS, INC., XP002208813 *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 04 30 April 1996 (1996-04-30) *
TRAXLER P M ET AL: "4-(PHENYLAMINO)PYRROLOPYRIMIDINES: POTENT AND SELECTIVE, ATP SITE DIRECTED INHIBITORS OF THE EGF-RECEPTOR PROTEIN TYROSINE KINASE", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 39, no. 12, 1 December 1996 (1996-12-01), pages 2285 - 2292, XP002053503, ISSN: 0022-2623 *

Cited By (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41783E1 (en) 1999-12-10 2010-09-28 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine compounds
US7803805B2 (en) 2001-12-06 2010-09-28 Pfizer Inc. Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt
US6965027B2 (en) 2001-12-06 2005-11-15 Pfizer Inc. Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
US8334296B2 (en) 2002-02-01 2012-12-18 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7820819B2 (en) 2002-02-01 2010-10-26 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7655797B2 (en) 2002-02-01 2010-02-02 Rigel Pharmaceuticals, Inc. Intermediates for making 2,4-pyrimidinediamine compounds
US7803939B2 (en) 2002-02-01 2010-09-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8158621B2 (en) 2002-07-29 2012-04-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US7358250B2 (en) 2004-06-29 2008-04-15 Amgen Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
JP2012140469A (en) * 2004-12-22 2012-07-26 Incyte Corp PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITOR
US7335667B2 (en) 2004-12-22 2008-02-26 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors
US9879010B2 (en) 2004-12-22 2018-01-30 Incyte Holdings Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors
US9580419B2 (en) 2004-12-22 2017-02-28 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors
EP2671882B1 (en) 2004-12-22 2018-02-21 Incyte Holdings Corporation pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors
US9090611B2 (en) 2004-12-22 2015-07-28 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
US8445488B2 (en) 2004-12-22 2013-05-21 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors
US8053433B2 (en) 2004-12-22 2011-11-08 Ineyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
US8741895B2 (en) 2004-12-22 2014-06-03 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors
US10421752B2 (en) 2005-06-08 2019-09-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9248190B2 (en) 2005-06-08 2016-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8399472B2 (en) 2005-06-08 2013-03-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11198689B2 (en) 2005-06-08 2021-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8415365B2 (en) 2005-06-08 2013-04-09 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11827628B2 (en) 2005-06-08 2023-11-28 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9593082B2 (en) 2005-06-08 2017-03-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9732073B2 (en) 2005-06-08 2017-08-15 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
US8232394B2 (en) 2005-07-29 2012-07-31 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
US8309716B2 (en) 2005-07-29 2012-11-13 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives: their intermediates and synthesis
US8563541B2 (en) 2005-09-22 2013-10-22 Incyte Corporation Azepine inhibitors of Janus kinases
US8835423B2 (en) 2005-09-22 2014-09-16 Incyte Corporation Azepine inhibitors of janus kinases
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US9814722B2 (en) 2005-12-13 2017-11-14 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US10398699B2 (en) 2005-12-13 2019-09-03 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US10639310B2 (en) 2005-12-13 2020-05-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9974790B2 (en) 2005-12-13 2018-05-22 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US11331320B2 (en) 2005-12-13 2022-05-17 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US7598257B2 (en) 2005-12-13 2009-10-06 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US8946245B2 (en) 2005-12-13 2015-02-03 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US11744832B2 (en) 2005-12-13 2023-09-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
US9662335B2 (en) 2005-12-13 2017-05-30 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US9206187B2 (en) 2005-12-13 2015-12-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
US7879844B2 (en) 2005-12-28 2011-02-01 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US11667611B2 (en) 2006-02-24 2023-06-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8841318B2 (en) 2006-12-22 2014-09-23 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
US7834022B2 (en) 2007-06-13 2010-11-16 Incyte Corporation Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8889697B2 (en) 2007-06-13 2014-11-18 Incyte Corporation Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10016429B2 (en) 2007-06-13 2018-07-10 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10610530B2 (en) 2007-06-13 2020-04-07 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10463667B2 (en) 2007-06-13 2019-11-05 Incyte Incorporation Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8822481B1 (en) 2007-06-13 2014-09-02 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8829013B1 (en) 2007-06-13 2014-09-09 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9376439B2 (en) 2007-06-13 2016-06-28 Incyte Corporation Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8541426B2 (en) 2007-07-11 2013-09-24 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
AU2008273804B2 (en) * 2007-07-11 2014-07-10 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
US9624229B2 (en) 2008-02-15 2017-04-18 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US8735418B2 (en) 2008-02-15 2014-05-27 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US8309566B2 (en) 2008-02-15 2012-11-13 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US8420629B2 (en) 2008-03-11 2013-04-16 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8952027B2 (en) 2008-04-16 2015-02-10 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8501944B2 (en) 2008-04-16 2013-08-06 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US10533001B2 (en) 2008-04-16 2020-01-14 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US11414410B2 (en) 2008-04-16 2022-08-16 Alexion Pharmaceuticals, Inc. Inhibitors of protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9868729B2 (en) 2008-04-16 2018-01-16 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8937070B2 (en) 2008-04-16 2015-01-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9579320B2 (en) 2008-04-16 2017-02-28 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9139581B2 (en) 2008-04-22 2015-09-22 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8299084B2 (en) 2009-04-20 2012-10-30 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of Janus kinase 3
US9493469B2 (en) 2009-04-20 2016-11-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of Janus kinase 3
US9856261B2 (en) 2009-04-20 2018-01-02 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of Janus kinase 3
US8962638B2 (en) 2009-04-20 2015-02-24 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9512161B2 (en) 2009-10-09 2016-12-06 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8633206B2 (en) 2009-10-15 2014-01-21 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine compounds
WO2011045702A1 (en) 2009-10-15 2011-04-21 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
US8372854B2 (en) 2009-12-18 2013-02-12 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine compounds
WO2011075334A1 (en) 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
WO2011097087A1 (en) 2010-02-05 2011-08-11 Pfizer Inc. Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US11285140B2 (en) 2010-03-10 2022-03-29 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US10695337B2 (en) 2010-03-10 2020-06-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US10869870B2 (en) 2010-05-21 2020-12-22 Incyte Corporation Topical formulation for a JAK inhibitor
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US11590136B2 (en) 2010-05-21 2023-02-28 Incyte Corporation Topical formulation for a JAK inhibitor
US11571425B2 (en) 2010-05-21 2023-02-07 Incyte Corporation Topical formulation for a JAK inhibitor
US11219624B2 (en) 2010-05-21 2022-01-11 Incyte Holdings Corporation Topical formulation for a JAK inhibitor
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
WO2012100948A1 (en) 2011-01-27 2012-08-02 Ratiopharm Gmbh Pharmaceutical compositions comprising tasocitinib
WO2012100949A1 (en) 2011-01-27 2012-08-02 Ratiopharm Gmbh Oral dosage forms for modified release comprising tasocitinib
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
WO2012135338A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Processes for preparing tofacitinib salts
AU2012241018B2 (en) * 2011-04-08 2015-11-12 Pfizer Inc. Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
JP2012219099A (en) * 2011-04-08 2012-11-12 Pfizer Inc Crystal pyrrolo[2,3-d]pyrimidine compound
WO2012137111A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
EP2524688A1 (en) 2011-05-11 2012-11-21 ratiopharm GmbH Composition for modified release comprising ranolazine
WO2012152440A1 (en) 2011-05-11 2012-11-15 Ratiopharm Gmbh Composition for modified release comprising ranolazine
US9023840B2 (en) 2011-06-20 2015-05-05 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US10513522B2 (en) 2011-06-20 2019-12-24 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US11214573B2 (en) 2011-06-20 2022-01-04 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
US11045474B2 (en) 2011-11-30 2021-06-29 Emory University Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US9662332B2 (en) 2011-11-30 2017-05-30 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US10022378B2 (en) 2011-11-30 2018-07-17 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US11065254B2 (en) 2011-11-30 2021-07-20 The United States Government As Represented By The Department Of Veterans Affairs Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
WO2013090490A1 (en) 2011-12-15 2013-06-20 Ratiopharm Gmbh Tofacitinib salts
EP3170826A1 (en) 2011-12-15 2017-05-24 ratiopharm GmbH Tofacitinib mono-malate salt
EP3170827A1 (en) 2011-12-15 2017-05-24 ratiopharm GmbH Tofacitinib mono-oxalate salt
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2014016338A1 (en) 2012-07-25 2014-01-30 Lek Pharmaceuticals D.D. New synthetic route for the preparation of 3-amino-piperidine compounds
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
US11896717B2 (en) 2012-11-15 2024-02-13 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11576865B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576864B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10874616B2 (en) 2012-11-15 2020-12-29 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11337927B2 (en) 2012-11-15 2022-05-24 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US9545405B2 (en) 2013-02-22 2017-01-17 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine derivatives
US9035074B2 (en) 2013-02-22 2015-05-19 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine derivatives
WO2014128591A1 (en) 2013-02-22 2014-08-28 Pfizer Inc. Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
US9549929B2 (en) 2013-02-22 2017-01-24 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine derivatives
EP3290421A1 (en) 2013-02-22 2018-03-07 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
US9221845B2 (en) 2013-03-06 2015-12-29 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
WO2014147526A1 (en) 2013-03-16 2014-09-25 Pfizer Inc. Tofacitinib oral sustained release dosage forms
EP3854400A1 (en) 2013-03-16 2021-07-28 Pfizer Inc. Tofacitinib oral sustained release dosage forms
US9937181B2 (en) 2013-03-16 2018-04-10 Pfizer Inc. Tofacitinib oral sustained release dosage forms
US10639309B2 (en) 2013-03-16 2020-05-05 Pfizer Inc. Tofacitinib oral sustained release dosage forms
EP4249055A2 (en) 2013-03-16 2023-09-27 Pfizer Inc. Tofacitinib oral sustained release dosage forms
US11253523B2 (en) 2013-03-16 2022-02-22 Pfizer Inc. Tofacitinib oral sustained release dosage forms
EP2813228A1 (en) 2013-04-25 2014-12-17 Japan Tobacco Inc. Agent for improvement of skin barrier function
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
US10561616B2 (en) 2013-08-07 2020-02-18 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US11045421B2 (en) 2013-08-07 2021-06-29 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
WO2015083028A1 (en) 2013-12-05 2015-06-11 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
US11111242B2 (en) 2013-12-05 2021-09-07 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
EP3318565A1 (en) 2013-12-05 2018-05-09 Pfizer Inc Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
US9617258B2 (en) 2013-12-05 2017-04-11 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
EP3539965A1 (en) 2013-12-09 2019-09-18 Unichem Laboratories Limited An improved process for the preparation of (3r,4r)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine
US9260438B2 (en) 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10966980B2 (en) 2014-08-12 2021-04-06 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US10617690B2 (en) 2015-01-20 2020-04-14 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitor
US20160297825A1 (en) * 2015-04-10 2016-10-13 Olon S.P.A. Efficient method for the preparation of tofacitinib citrate
EP3078665A1 (en) 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
US9828380B2 (en) * 2015-04-10 2017-11-28 Olon S.P.A. Efficient method for the preparation of tofacitinib citrate
US10174036B2 (en) 2015-04-29 2019-01-08 Wuxi Fortune Pharmaceutical Co., Ltd Substituted pyrazoles as JAK inhibitors
US10703756B2 (en) 2015-05-01 2020-07-07 Pfizer Inc. Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof
WO2016178110A1 (en) 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
US10174056B2 (en) 2015-05-29 2019-01-08 Wuxi Fortune Pharmaceutical Co., Ltd Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2017125417A1 (en) 2016-01-18 2017-07-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Tofacitinib as vaccination immune modulator
WO2018004306A1 (en) 2016-06-30 2018-01-04 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
EP3950691A1 (en) 2016-06-30 2022-02-09 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
US10961247B2 (en) 2016-06-30 2021-03-30 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
US11084823B2 (en) 2017-03-17 2021-08-10 Daewoong Pharmaceutical Co., Ltd. Substituted pyrrolo[2,1-f][1,2,4]triazines as kinase inhibitors
WO2018169373A1 (en) 2017-03-17 2018-09-20 Daewoong Pharmaceutical Co., Ltd. Pyrrolotriazine derivatives as kinase inhibitor
KR20190064215A (en) 2017-11-30 2019-06-10 보령제약 주식회사 Pharmaceutical Composition Comprising Tofacitinib
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019132560A1 (en) 2017-12-28 2019-07-04 주식회사 대웅제약 Amino-fluoropiperidine derivative as kinase inhibitor
US11078206B2 (en) 2017-12-28 2021-08-03 Daewoong Pharmaceutical Co., Ltd. Amino-fluoropiperidine derivatives as kinase inhibitor
US11339167B2 (en) 2017-12-28 2022-05-24 Daewoong Pharmaceutical Co., Ltd. Substituted piperidines as kinase inhibitors
WO2019132562A1 (en) 2017-12-28 2019-07-04 주식회사 대웅제약 Oxy-fluoropiperidine derivative as kinase inhibitor
US11407754B2 (en) 2017-12-28 2022-08-09 Daewoong Pharmaceutical Co., Ltd. Substituted piperidines as kinase inhibitors
WO2019132561A1 (en) 2017-12-28 2019-07-04 주식회사 대웅제약 Amino-methyl piperidine derivative as kinase inhibitor
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US20190231782A1 (en) * 2018-01-31 2019-08-01 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
US10960006B2 (en) * 2018-01-31 2021-03-30 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
KR102131107B1 (en) 2019-01-15 2020-07-07 주식회사 다산제약 Novel method for preparing 3-amino-piperidine
WO2020198583A1 (en) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Bicyclic jak inhibitors and uses thereof
EP3927689A4 (en) * 2019-04-05 2022-11-30 Yuhan Corporation Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
WO2021094953A1 (en) 2019-11-14 2021-05-20 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
EP4067354A1 (en) 2019-11-25 2022-10-05 Daewoong Pharmaceutical Co., Ltd. Novel triazolopyridine derivative and pharmaceutical composition comprising same
WO2021107590A1 (en) 2019-11-25 2021-06-03 주식회사 대웅제약 Novel triazolopyridine derivative and pharmaceutical composition comprising same
WO2021198980A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022194782A1 (en) * 2021-03-15 2022-09-22 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib

Also Published As

Publication number Publication date
HUP0400152A3 (en) 2012-12-28
FR17C1031I1 (en) 2017-10-13
CZ20033260A3 (en) 2004-03-17
CU23337B7 (en) 2009-01-20
EP1666481A3 (en) 2006-11-29
EP1666481A2 (en) 2006-06-07
CY2017028I1 (en) 2018-02-14
BR0209246A (en) 2004-06-15
GEP20063784B (en) 2006-04-10
HUP0400152A2 (en) 2007-07-30
PL409305A1 (en) 2014-12-22
CA2448281A1 (en) 2002-12-05
ES2393385T3 (en) 2012-12-20
AP2002002550A0 (en) 2002-06-30
AR045680A2 (en) 2005-11-09
CN1729192A (en) 2006-02-01
EA200600575A1 (en) 2006-08-25
AU2002304401B2 (en) 2008-04-17
EE05332B1 (en) 2010-08-16
AP1859A (en) 2008-07-02
EP1666481B9 (en) 2013-05-01
NO2017047I1 (en) 2017-09-08
UY27317A1 (en) 2003-02-28
FR17C1031I2 (en) 2018-11-02
LTPA2017025I1 (en) 2017-09-11
TNSN03128A1 (en) 2005-12-23
NO20035201L (en) 2003-11-24
KR20080002931A (en) 2008-01-04
CY1113322T1 (en) 2016-06-22
HU230876B1 (en) 2018-11-29
US20040229923A1 (en) 2004-11-18
MA27029A1 (en) 2004-12-20
TW200413370A (en) 2004-08-01
TWI310384B (en) 2009-06-01
ATE519741T1 (en) 2011-08-15
HRP20030943A2 (en) 2005-08-31
YU92303A (en) 2006-08-17
IL158588A0 (en) 2004-05-12
AU2008203170B2 (en) 2009-06-18
ECSP034865A (en) 2004-01-28
EP1392694A1 (en) 2004-03-03
PL228155B1 (en) 2018-02-28
PL367945A1 (en) 2005-03-07
DK1666481T3 (en) 2012-10-15
GT200200100AA (en) 2007-07-06
MY129649A (en) 2007-04-30
NO328578B1 (en) 2010-03-22
BE2017C032I2 (en) 2021-07-19
KR20060014459A (en) 2006-02-15
GT200200100A (en) 2003-02-11
SK14652003A3 (en) 2004-05-04
IS6993A (en) 2003-10-13
EA007251B1 (en) 2006-08-25
KR100926875B1 (en) 2009-11-16
KR20060133117A (en) 2006-12-22
CL2008000762A1 (en) 2008-07-04
EA200301193A1 (en) 2004-04-29
AU2008203170A1 (en) 2008-08-07
EP1609781B1 (en) 2011-08-10
HUS1900008I1 (en) 2020-02-28
KR20080083028A (en) 2008-09-12
PT1666481E (en) 2012-12-03
SI1666481T1 (en) 2012-11-30
CZ304366B6 (en) 2014-04-02
KR20040003037A (en) 2004-01-07
BG66489B1 (en) 2015-05-29
HRP20030943B1 (en) 2011-11-30
EP1666481B1 (en) 2012-09-19
US20030073719A1 (en) 2003-04-17
LUC00031I2 (en) 2017-10-11
NZ540332A (en) 2007-05-31
CA2448281C (en) 2009-05-05
ES2369226T3 (en) 2011-11-28
IS3023B (en) 2020-08-15
NO20093135L (en) 2003-11-24
KR100869409B1 (en) 2008-11-21
US7301023B2 (en) 2007-11-27
AR037321A1 (en) 2004-11-03
EA012666B1 (en) 2009-12-30
SK288199B6 (en) 2014-06-03
US7432370B2 (en) 2008-10-07
LUC00031I1 (en) 2017-08-10
JP4381137B2 (en) 2009-12-09
KR100868814B1 (en) 2008-11-14
OA12612A (en) 2006-06-09
JP2004534047A (en) 2004-11-11
SK288192B6 (en) 2014-06-03
ZA200307982B (en) 2004-10-14
CY2017028I2 (en) 2018-02-14
BG108389A (en) 2005-01-31
NO20035201D0 (en) 2003-11-24
AU2002304401C1 (en) 2009-03-05
NL300887I2 (en) 2017-08-31
UA80093C2 (en) 2007-08-27
RS52144B (en) 2012-08-31
EP1609781A1 (en) 2005-12-28
EE200300594A (en) 2004-04-15
MXPA03011062A (en) 2004-03-19
TWI316061B (en) 2009-10-21
PE20030561A1 (en) 2003-06-23
LTC1666481I2 (en) 2018-06-25
PA8546301A1 (en) 2003-05-14
NZ530380A (en) 2005-08-26
CR10177A (en) 2008-08-19

Similar Documents

Publication Publication Date Title
EP1666481B9 (en) 3-((3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidinyl)-3-oxo-propionitrile as protein kinase inhibitor
AU2002304401A1 (en) Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
AU784297B2 (en) Pyrrolo(2,3-d)pyrimidine compounds as immunosuppressive agents
AU2003276591A1 (en) Method of treatment of transplant rejection
AU1295001A (en) Pyrrolo(2,3-d)pyrimidine compounds
EP1689407A1 (en) Method of treatment of atherosclerosis
WO2005060972A2 (en) Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-923/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003/07982

Country of ref document: ZA

Ref document number: 200307982

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 03094619A

Country of ref document: CO

Ref document number: 03094619

Country of ref document: CO

Ref document number: 158588

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002304401

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 149/MUMNP-WTO/2003

Country of ref document: IN

Ref document number: 991/MUMNP/2003

Country of ref document: IN

Ref document number: 00991/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002733058

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P20030943A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2448281

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1-2003-501204

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 10838902

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2003-3260

Country of ref document: CZ

Ref document number: 2003500088

Country of ref document: JP

Ref document number: 028108175

Country of ref document: CN

Ref document number: 1200301077

Country of ref document: VN

Ref document number: 14652003

Country of ref document: SK

Ref document number: 5361

Country of ref document: GE

Ref document number: 200301193

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020037015681

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/011062

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 530380

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2002733058

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-3260

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002733058

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 530380

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 530380

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020067001821

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020067025590

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020077025832

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12008501692

Country of ref document: PH

Ref document number: 12008501693

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1020087018519

Country of ref document: KR